Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 25, 2026.

Physiology and Physical Chemistry of Bile Acids

Maria Chiara di Gregorio, Jacopo Cautela, Luciano Galantini

International Journal of Molecular Sciences · 2021 · Review · CC BY

doi:10.3390/ijms22041780

Abstract

Bile acids (BAs) are facial amphiphiles synthesized in the body of all vertebrates. They undergo the enterohepatic circulation: they are produced in the liver, stored in the gallbladder, released in the intestine, taken into the bloodstream and lastly re-absorbed in the liver. During this pathway, BAs are modified in their molecular structure by the action of enzymes and bacteria. Such transformations allow them to acquire the chemical–physical properties needed for fulling several activities including metabolic regulation, antimicrobial functions and solubilization of lipids in digestion. The versatility of BAs in the physiological functions has inspired their use in many bio-applications, making them important tools for active molecule delivery, metabolic disease treatments and emulsification processes in food and drug industries. Moreover, moving over the borders of the biological field, BAs have been largely investigated as building blocks for the construction of supramolecular aggregates having peculiar structural, mechanical, chemical and optical properties. The review starts with a biological analysis of the BAs functions before progressively switching to a general overview of BAs in pharmacology and medicine applications. Lastly the focus moves to the BAs use in material science.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 25, 2026. Paragraph numbers are ours, so an answer can point at one.

1. Introduction

Bile acids (BAs) constitute an important class of biological molecules produced in the metabolism of all vertebrates. In mammals, they exhibit the so called C24 structure: 24 carbon atoms form a steroid nucleus (three six-member rings indicated as A, B C and a five-member ring indicated as D) and a five-carbon side chain with a carboxyl group at the C-24 position.

The A and B rings are linked in cis configuration, inducing an overall bent shape. Such a structural feature delineates a concave and convex side of the steroidal backbone where OH groups in α orientation (up to three) and two methyl groups in β orientation, respectively, point out. Therefore, two opposite faces with hydrophilic and hydrophobic properties can be distinguished. (Figure 1a,b). Further variations of the molecular structure can be observed at C-3 carbon due to hydroxyl, sulfate or glucuronate substituents. C-6 and C-24 glucoronide conjugates were also found in humans. Other C-24 substituents are glycine or taurine. Recently Dorrestein et al. reported new amino acid C-24 substituted cholic acid (CA) namely phenylalanocholic, tyrosocholic and leucocholic acid. BA actions generally occur in conditions where they are deprotonated; for this reason, many authors refer to them as bile salts instead of acids. In this review the term BA will be used keeping in mind that we refer mostly to their salt form.

According to the order in which they are produced in the human body, BAs are differently named. CA and chenodeoxycholic (CDCA) acids—3 and 2 OH groups, respectively—are first synthesized by the hepatocyte and thus named primary BAs. Subsequently CA and CDCA are conjugated to glycine or taurine, giving rise to glycocholic (GCA), taurocholic (TCA) acids and glycochenodeoxycholic (GCDCA), taurochenodeoxycholic (TCDCA) acids, respectively. Further metabolization leads to the secondary BAs, deoxycholic (DCA) and lithocholic (LCA) acids, that present two and one OH groups, respectively (Figure 1c,d). The increase in the hydrophobic character, moving from primary to secondary BAs, affects the BA chemical–physical and physiological properties, making them differently active in the diverse parts of the enterohepatic circuit.

Generally speaking, five major physiological roles can be distinguished in BA activity: (1) regulation of cholesterol homeostasis; (2) deterrence for the formation of gallstones and kidney stones; (3) emulsification of dietary lipids and absorption of fat-soluble vitamins; (4) antimicrobial activity; (5) regulation function.

These functions will be described in the next paragraphs, following the BA physiological pathway—from biosynthesis to elimination/recirculation.

BAs are produced in the liver and stored in the gallbladder. Subsequently they are secreted through the biliary tract in the intestine, absorbed in the intestinal epithelium to pass into the portal circulation and return to the liver. The overall process is named enterohepatic circulation. A small part of BAs escapes this cycle being secreted through the feces. The daily loss of BAs is compensated by new liver production.

2. Synthesis in the Liver and Storage in the Gallbladder: BAs in Cholesterol Metabolism

BAs are produced in their primary forms (CA and CDCA) in the liver, adopting cholesterol as starting substrate and the activity of 16 enzymes. Such enzymes catalyze 17 different reactions. In humans, the synthesis takes place in multiple intracellular compartments such as the cytosol, endoplasmic reticulum, mitochondria and peroxisomes.

A living organism can exploit two different synthetic routes for the BA synthesis.

The route, that is quantitively more important for adult humans, is known as “classic or neutral path” and provides for more than 90% of the BA needs. Such a synthetic pathway starts with the hydroxylation of the sterol ring on C7 mediated by the cholesterol 7α-hydroxylase (CYP7A1). Subsequently the intermediate is immediately modified on the lateral chain by the sterol 27-hydroxylase (CYP27) for the CDCA synthesis or, in the case of the CA synthesis, is further hydroxylated on C-12 by the 12α-hydroxylase (CY8B1) before the CYP27 catalyzed step. In this pathway, the CYP7A1 activity is the kinetic key that determines the overall rate of the metabolic pathway. On the other hand, the CY8B1 activity, modulating the hydrophilicity composition of the steroid nucleus, controls the CA and CDCA production ratio.

The second biosynthetic route, named “acidic path”, leads to the production of CDCA in humans and it is dominant in human neonates. In this pathway the chemical modifications of the cholesterol substrate involve first the lateral chain where a hydroxyl group is introduced on C27 by the CYP27 activity. Subsequently the modification of the sterol part is performed by the oxysterol 7α-hydroxylase (CYP7B1). A minority fraction of C25- and C24-hydroxycholesterols generated by the corresponding hydroxylases can also enter the acidic pathway to form BAs. Although most of the hydroxycholesterols are produced in the liver, hydroxycholesterols generated in extra hepatic tissues, such as lungs and brain, may be transported to the liver and be also involved in this BAs biosynthetic route. After their synthesis, CA and CDCA are conjugated to taurine and glycine by the activity of two enzymes, bile acid-CoA synthase and bile acid-CoAamino acid N-acyltransferase. The conjugation makes the produced BA more hydrophilic and more acidic on the side chain: the pKa decreases from ~5.0 to ~3.9 and <2 for glycine and taurine conjugates, respectively. The amount of synthesized BA is regulated by control mechanisms that operate at transcriptional level, where the transcription factors are nuclear receptors. An exceeding amount of BA triggers a negative feedback mechanism, starting with the BAs binding to the hepatic farnesoid X receptor (FXR) and ending with the inhibition of the genes expressing the CYP7A1 and CYP8B1 enzymes involved in the biosynthesis of BA. The activation of FXR affects not only the synthesis itself but it also regulates the level of the BA in the intestine and biliary tree. Indeed, in order to assure concurrently an efficient lipid absorption and a sustainable hepatic level of BA, the FXR increases the expression of the transporters which mediate the efflux of the BA into the biliary canaliculi. At the same time, it suppresses the expression of the importer NTCP, thus reducing the BA reabsorption from the blood into the hepatocytes. Besides the effect in the liver, reabsorbed BAs can bind also the intestinal FXR in the distal ileum, activating it. The activated FXR stimulates in turn the expression of the fibroblast growth factor 19 (FGF19) and its release into the portal blood. Once it reaches the hepatocyte plasma membrane, FGF19 binds the FGF receptor 4 (FGFR4)/β-klotho complex, triggering a signaling cascade that results in the suppression of the CYP7A1 mRNA and thus the suppression of the CYP7A1 expression.

BA production utilizes a consistent amount of the cholesterol pool (about 500 mg per day), thus turning out to be one of the main mechanisms for cholesterol regulation in the human body. Consistently, hypercholesterolemia is often treated by Bas sequestrants. It has been observed that certain animals when fed with hypercholesterolic diet manage to keep normal the plasma cholesterol level, thanks to a compensating mechanism that increases the production of BAs. BAs sequestrants are generally formed by cationic polyelectrolytes, which are able to bind the BAs through both electrostatic and hydrophobic attractive interactions and as such to remove them from the enterohepatic circulation. Sequestration stimulation increased conversion of cholesterol into BAs in the liver, thereby leading to the lowering of the LDL (low-density lipoproteins, “bad”) cholesterol in the blood, and simultaneously to an increase in the HDL (high-density lipoproteins, “good”) cholesterol and triglycerides. BA sequestrants are also used in the medical treatment of BA related diseases, such as BA diarrhea caused by BAs in the large intestine or colon due to the malabsorption of BA in the small intestine (secondary BA diarrhea) or BA overproduction resulting from defective feedback inhibition of the biosynthesis of BAs in the liver (primary BA diarrhea). In the treatment, sequestrants bind BAs, hinder them from contact with the colonic mucosa, thereby decreasing the BA level in the colon. BA sequestrants can also reduce glucose levels in patients with type 2 diabetes mellitus, although the mechanism of action still remains unclear. Moreover, BAs malabsorption reduces the amount of BA in the small intestine inducing fat maldigestion and consequent steatorrhea as occurring in patients with short bowel syndrome. Consequently, the maldigested fatty acids in the small intestine complex the luminal Ca, lowering the fraction of Ca available for the dietary oxalate precipitation. In turn, the oxalate remains as free ions and is hyperabsorbed by the colon, leading to hyperoxaluria and increasing the possibility of kidney stone formation. Oral therapies based on natural and synthetic conjugated bile salts were observed to decrease fecal fat and urinary oxalate execration in patients with short bowel syndrome.

A further important role of BAs towards cholesterol concerns the solubilization activity in the bile. Cholesterol is majorly eliminated through the secretion in bile. Bile is a solution produced in the liver that is composed by 95% of water. Free cholesterol is insoluble in aqueous solutions. However, in bile due to the presence of BAs (about 0.7%) and lipids like lecithin, cholesterol is easily solubilized through the formation of mixed micelles. Such a process avoids the cholesterol supersaturation and in turn the formation of gallstones. The interaction between cholesterol and BAs has been analyzed both from a chemical and medical point of view. In the first case, several studies analyzed the structure, stability and parameter formation of BAs–cholesterol-based micelles and crystals. In the latter case, CDCA was proved in the 1970s as successful molecule for dissolution of cholesterol gallstones. However, its use was lately abandoned because of the occurrence of side effects. The more hydrophilic ursodeoxycholic acid (UDCA) and its taurine conjugate started to be investigated as alternative treatment for cholelithiasis and their use in oral therapy is still ongoing, albeit restricted to a specific target group of patients (e.g., patients having gallstones due to temporary and non-genetic causes). The combined efficiency of UDCA and polyunsaturated fatty acids in dissolving cholesterol gallstones in mice was recently reported by Lee et al..

After the synthesis, conjugated BAs are transferred into bile, passing through the hepatocyte’s membrane to the canaliculi via the bile salt export pump. The bile in the canaliculi converge in a series of ducts that eventually terminate into the common hepatic duct. Via the hepatic duct, the bile reaches the gallbladder, where it is stored or is delivered directly to the intestinal lumen.

3. From the Gallbladder to the Intestine: Lipid Solubilization and Absorption

After a meal, the cholecystokinin hormone is released and its presence is the signal for the gallbladder to release bile. At this point the aminoacidic conjugation is functional for the BA activities since it allows for the transits to the small intestine via the biliary tree. Indeed, being completely ionized at the pH of biliary tract and small intestine, conjugated BAs cannot diffuse through the cell membranes, thus assuring consistent intraluminal concentration in the intestine for lipid digestion. Moreover, the conjugated BAs are less prone than unconjugated BAs to precipitate in presence of high concentration of Ca2+ ions. In the distal small intestine, bacteria break the conjugation with the aminoacidic of a fraction of conjugated BAs. Deconjugation is completed in the colon where further modifications as dihydroxylation and epimerization occur to give rise to secondary BAs, i.e., DCA, LCA and UDCA. Recently, anaerobic in vitro reconstitution experiments showed that six enzymes are sufficient for the conversion of cholic acid into DCA.

At any time, a portion of 85–90% of BAs is present in the small intestine. Here BAs have several roles in the digestion of lipids, ranging from emulsification to transport (Figure 2a). Lipid digestion starts in the stomach where the food is initially broken down by the mechanical action of peristalsis and by the chemical activity of gastric juices. Subsequently the digestion continues in the duodenum where the partially digested food mixes with digestive enzymes from the pancreas—pancreatic lipase—and BAs. At this stage, the ingested lipids are in the form of oil-in-water emulsion stabilized by different surface-active substances such as proteins and phospholipids. In order to hydrolyze lipids into simpler and absorbable molecules, lipase and its co-factor co-lipase have to anchor on the droplet surface. The first crucial role of BAs is to increase the bioavailability of the lipid substrates to the enzyme by displacing the different stabilizers at the water–oil interface. Subsequently BAs indirectly help the positioning of lipase on the lipidic substrate by favoring the interfacial adsorption of co-lipase. After the lipase activity, lipids are decomposed in free fatty acids and monoglycerides. These products remain at the oil–water droplet interface until BAs englobe them in mixed micelles, thereby providing their removal and transport through the intestinal mucus.

The fundamental understanding of these mechanisms is supported by a large collection of literature that by means of microscopic, spectroscopic and rheological techniques, (i) analyzed the displacement mechanism of BAs with respect to a large number of proteins and lipids (Figure 2b), (ii) demonstrated the improved activity of lipase in presence of BAs, (iii) elucidated the mechanism of lipid transport through the intestinal mucus. Besides clarifying the physiological mechanism, such knowledges turn out to be essential for food and drug industry in order to engineer efficient strategies for drugs, dietary lipids and sugars uptake in the gastrointestinal tract.

4. Antimicrobial Activity

BAs and gut microbiota have a mutual interaction. As aforementioned, the molecular structures of primary BAs are modified by the gut bacteria to give rise to secondary BAs or other BA forms that escape the enterohepatic circulation. Nevertheless, also BAs influence the microbiota composition. Concerning the latter point, it has been for example observed that low levels of BAs in the gut induce an overgrowth of bacteria and potential pathogens, increasing the occurrence of inflammations and bacterial translocation. This is due to the fact that BAs have relevant antimicrobial activities. The BAs antimicrobial activity can be mainly related to two different action mechanisms. The first one refers to the detergent properties of BAs and their ability to penetrate and break membranes (Figure 3a–c). In vitro experiments proved that BAs can provoke hemolysis in erythrocytes due to BA-induced membrane damages. Similarly, cells were observed to shrivel under BAs exposure and release intracellular materials. Fast and drastic decomposition of membrane proteins occurs at high BA concentrations. Sub micellar BA concentrations can also alter membrane permeability by interacting with membrane-bounded enzymes/proteins, by changing the transmembrane flux of divalent cations or by inducing hydrophobicity and external charge modification of the cells. Antimicrobial activity due to detergent properties is particularly strong in unconjugated BAs. Indeed, unconjugated BAs can passively penetrate through the lipid bilayer by the “flip-flop” mechanism and access the cells. The kinetic of the penetration process is strongly affected by the number of hydroxyl groups, becoming more efficient as the number of hydroxyl group decreases. Consistently antimicrobial activity of DCA was proved in vitro to be an order of magnitude higher than that of CA. On the other hand, conjugated BAs are strong acids and are fully ionized at physiological pHs. In the absence of a specific transport system, this feature inhibits the BA penetration through the membrane, favoring instead the BA adhesion on the external part of the bilayers. In vitro studies showed that such adhesion varies the membrane surface properties that, although destabilizing cell integrity, induce less membrane damage than the unconjugated analogues. Despite the in vitro results, in vivo experiments suggested relevant antibacterial properties related to the presence of conjugated BAs. It was for example observed that events that decrease conjugated BA secretion in animals, such as liver cirrhosis or bile duct ligation, induce an increase in the bacterial growth (Figure 3d–f). Similarly, upon feeding of conjugated BAs and bile in BAs-deficient intestines, overgrowth of bacteria was suppressed. Such contradiction was solved by Inagaki and coworkers in 2006 who showed an alternative antibacterial mechanism of BAs. It was proved that conjugated BAs are natural ligands of the nuclear receptor farnesoid X (FXR) that in turn activate the expression of genes whose products (e.g., nitric oxide) stop bacterial overgrowth. Such a mechanism occurs in the distal small intestine that turns out to host a poor fraction of microbes (about 104 to 105 colony-forming units/mL), a high concentration of conjugated BAs (about 10 mM during digestion time) and an FXR level three times higher than the epithelium of the proximal small intestine.

Moreover Kang et al. recently discovered that the bile acid 7a-dehydroxylating gut bacteria, responsible for the biotransformation of primary BAs into secondary BAs, secrete tryptophan and proline-based antibiotics. Such antibiotics are able to obstruct bacterial pathogens causing diarrhea and colitis and their efficiency is enhanced in presence of DCA and LCA. Commensal gut bacteria were also demonstrated to have a regulating function towards liver cancer by using BAs as signaling molecules. Indeed, BAs through the portal vein reach the liver sinusoidal endothelial cells and regulate the accumulation of natural killer T cells, which in turn inhibits the liver tumor growth. It was found in particular that the accumulation of the natural killer T cells was favored by primary BAs and disfavored by secondary ones.

To conclude this paragraph, it has to be emphasized that the enteric flora in the human body can have protecting functions, by for example eliciting immune responses, but can be also responsible for pathologies such as inflammatory bowel disease and cancers. Therefore, the resistance of bacteria to the bile toxicity turns out to be one of the key mechanisms used by the human body to select probiotic strains that can positively perform in the gastrointestinal tract. The functions showed in the physiological environment can be modified/amplified by covalently or not-covalently combining the natural BAs with other moieties/molecules. The huge possibilities offered by modern organic chemistry has made the BAs functionalization more and more complex. Novel synthetic procedures have allowed for precise control on stereospecific substitutions, polymerization processes, introduction of differently charged groups and derivatization of concurrent and multiple positions on the original molecular structure.

The BA ability to penetrate membranes has been boosted up in derivatives, enabling for preparation of active molecule carriers where the BA derivatives (BADs) can work both as monomer (e.g., by the specific interaction with proteins membrane) or in aggregates (e.g., by the formation of drugs including transferosomes, vesicles, micelles, gels). BAs emulsification properties have been investigated to formulate new drugs for treatment of obesity and other diseases related to slow fat assimilation and high levels of cholesterol (e.g., lithiasis). Starting from the regulatory functions of BAs, BADs have also been developed to interfere in several physiological pathways (e.g., glucose, lipid and energy metabolism) for the treatment of metabolic syndromes.

5. Functionalized BAs in Medicine

In the light of their biological origin and the specific interaction with several physiological pathways, BA and BADs have naturally become the protagonist of many biomedical and pharmaceutical studies. For example, antimicrobial activity of natural BAs has been used in traditional Chinese Medicine in environments different to the physiological one, e.g., in treatment of skin laceration or for reduction in swelling, pain and fever.

Both natural BAs and a large number of BADs have been proved efficient against many bacteria, parasites, fungi and to induce apoptosis in different types of cancerogenic cells. To mention some examples, it has been known for more than a decade that LCA induces apoptosis in neuroblastoma, breast cancer, prostate cancer cells, although recently its selective effects on nephroblastoma and sarcoma cell-lines was questioned. UDCA turned out to both favor and block apoptotic processes in different types of cells, according to the dosage and administration time. At low dose, UDCA efficiency has been proved in blocking lung cancer cell migration and propagation of colon and liver cancer cells. Better performance and lesser occurrence of side-effects have been shown when UDCA is used in combination with other anticancer drugs. BA molecules have also been used as a platform for the synthesis of BA-based anticancer drugs recently overviewed. Synthetic C24 aminoacid conjugated BA such as CDCA and UDCA acids have been reported to induce apoptosis in several human cancer cells like calf pulmonary endothelial cancer cells, hepatocellular carcinoma cells, breast carcinoma cells, leukemic T cells, prostate, colon and gastric cancer cells. Piperazinil derivatives of CDCA and UDCA has been proved to be active anticancer drugs. Heparin containing C24 modified DCA was reported to be able to limit migration and adhesion of cancer cells to extracellular matrix and to inhibit formation of metastasis. Functionalization at C3, C7 and C12 with groups containing positive trimethyl ammonium heads was observed to show enhanced cytotoxicity compared to the precursor BA. C24 substituted CA derivatives containing phenyl, benzothiazole, and four methylphenyl groups via aminoacid linkers showed good activity against breast and glioblastoma cancer cell lines. Recently dihydroartemisinin–UDCA derivatives were reported to improve the cytotoxicity of dihydroartemisinin towards leukemia cells and hepatocellular carcinoma. A deoxycholic acid-Camptothecin conjugate was recently proved by Xiao et al. to enhance the targeted delivery of anticancer molecules in liver by exploiting the specific BA-BA receptors interaction. A series of nucleoside and platinum(II)-BADs were screened to test the cytotoxic activity in different tumor cell lines. A bioconjugate of 4-nitro-3-(trifluoromethyl)-aniline with UDCA was proposed by Navacchia et al. as photochemotherapeutic agent thanks to its ability to release the antimicrobial and antioxidant agent NO upon visible light input. Different moieties were introduced on the BAs scaffold to inhibit the activity of Tyrosyl-DNA phosphodiesterase 1 that is an enzyme involved in removing DNA damage caused by the anticancer topoisomerase I poison drugs.

Antimicrobial activity is mainly based on the ability of BAs to damage membranes resulting from their amphiphilic steroidal structure. In addition, BAs can hinder bioenergetics processes by intracellular acidification, reducing proton motive forces, DNA damaging and protein denaturation. Based on the antimicrobial activity of natural BAs, BADs have been synthesized to be used as antifouling agents. Moreover, a class of BA-based antibiotics termed Ceragenins have been prepared by covalently attaching amines to BAs, inspired by the molecular structure of squalamine, a naturally occurring aminosterol with potent antimicrobial activity, isolated from shark liver. Similar molecules have been linked as pendants to polymers able to locally cluster the facial amphiphilicity of these cationic steroid antibiotics, thereby enhancing interactions with bacterial membranes (Figure 3g–i). To date, BAs are actually used both as precursor and co-agent in drug formulation. BA-drug conjugates have been synthesized to make the drug target liver and to enhance its intestinal absorption, by exploiting the ability of the conjugate to enter the enterohepatic circulation exploiting the BA transport system. Based on these principles, BA-based nanocarriers and BADs have been synthesized to target the apical sodium-dependent BA transporter with inhibitors, antiviral and anticancer drugs. Moreover, drugs against hepatitis C virus and anticancer cytostatic drugs have been specifically targeted to the liver upon conjugation with BAs. With the emergence of the COVID-19 pandemic, natural and synthetic BAs derivatives have also been investigated as anti-SARS-CoV2–2 agents.

6. BA-Based Polymers

BAs can be used in the preparation of polymers with a main interest in drug delivery. The presence of the carboxylic and hydroxyl groups on their molecule allows them to anchor polymer chains or to join into BA-based chains. BA containing polymers have been extensively investigated and recently overviewed by Zhu and co-workers. According to the former approach, BAs can be used as templates onto which polymers are grown, by exploiting the hydroxyl and the carboxylic groups as junctions for polymer chains, thereby providing star polymers. The star polymers self-assemble into micelles with a hollow-core able to encapsulate large drug loads, which depends on the number of BA hydroxyl groups (i.e., the number of polymer branches) (Figure 4a,b). The doxorubicin-loading ability of star polymers formed by poly(allyl glycidyl ether) and poly(ethylene glycol) grafted from the CA was recently analyzed, showing that a particularly high loading is achieved by exploiting electrostatic interactions. In addition, a remarkable cellular internalization was observed for the loaded carrier. BAs can be also introduced as pendant groups in block copolymers and thereby used to tune their properties and functionalities such as pH- and thermo-responsiveness and self-healing properties (Figure 4c,d). The investigation of the aggregates formed by these macromolecules has been promoted for their potential in drug and gene delivery applications.

Polymers formed by BAs as repeating units in the main chain, have also been synthesized with branched or linear architectures, mainly studied for their elastomeric and shape memory properties. CA has also been introduced as pendants in the hydrophobic diblock copolymers containing a glucosamine-based hydrophilic block, for bio-related applications. It was demonstrated that the self-assembly of the block copolymer could be tuned by changing the length of the blocks to provide micelle with optimal drug loading ability. Recently a block copolymer containing a dextran block linked to semi-rigid deoxycholic acid-oligo ethylene glycol polyester, was investigated, which showed a rich self-assembly involving star-shaped and wormlike micelles and vesicles depending on the dextran block length.

7. BA Lipid Mixtures

BAs and lipids can form mixed micelles exploited to solubilize hydrophobic drugs and to improve their bioavailability BA containing liposomes, sometimes named bilosomes, can be also prepared by intercalating BAs in the liposome lecithin bilayer. Bilosomes are preferentially used to deliver oral administrated drugs and vaccines due to their ability to stand acid conditions, enzyme attack and bile salt degradation in the gastrointestinal track compared to pure liposomes. They have also been observed to increase the absorption of oral administrated insulin and to facilitate transdermal drug delivery.

8. BA Polymer Mixtures

Biocompatible polymers are versatile systems widely exploited in applications. Based on their composition and sample conditions they can be available as solids, free chains, covalently crosslinked nano- and micro-gels or self-assembled nanoparticles, thus providing a platform adaptable for performances in several fields including drug delivery, tissue engineering, sensors, and catalysis. Interactions of BAs with cationic polymers are crucial for sequestration in the treatment of BA malabsorption or hypercholesterolemia. However, there is room for improvement of the currently used sequestrants of water-insoluble cationic hydrogels that have poor patient compliance and recently some reports on new polymeric BA sequestrants have appeared in the literature. Block copolymers able to strongly interact both electrostatically and hydrophobically with BAs have been proposed as compelling alternative sequestrants. Investigations on the interaction between BAs and poloxamers have recently demonstrated that BAs can be adsorbed on the corona of block copolymer micelles, thereby promoting block copolymers as alternative BA sequestrants. Similar Pluronic/BA mixed micelles were proven to be appealing drug-delivery vehicles and to efficiently load drugs like Clozapine and Doxorubicin. Because the BAs are anionic surfactants, it is expected that cationic block copolymers provide better BA binding and sequestration. Therefore, in a recent paper the co-assembly in dilute aqueous solution was reported in mixtures of diblock copolymer constituted of one poly(N-isopropyl acryl amide) (PNIPAM) block and a cationic polymer block of poly(3-acrylamidopropyl)-trimethylammonium chloride (PAMPTMA(+)) and the oppositely charged BA surfactant sodium deoxycholate. Two kinds of mixed aggregates were observed to form at room temperature having a globular morphology or a longitudinally striped tape-like architecture, which have a roughly neutral zeta potential at all compositions of the mixtures (Figure 4e–g). It was also found that the loss of water-solubility of PNIPAM with increasing temperature induces pronounced aggregation at a transition temperature, to provide aggregates with an interior containing dehydrated PNIPAM and a remarkably positive or negative charge depending on the mixture composition, thereby promoting the block copolymer–BA complex as versatile smart material for nanotechnological application. It was also demonstrated that precipitation of the complexes occurs at large fraction of BA as those encountered by sequestrants in the gastrointestinal track. A thermoresponsive BAD was observed to interact with the same catanionic block copolymer to form a complex, for which an intriguing thermoresponse was revealed by scattering techniques and circular dichroism measurements.

Polymeric carriers for the oral administration of drugs are expected to interact with BAs, which may affect the drug solubilization and absorption. With this motivation, the interaction in mixtures of sodium taurocholate and widely used hydrophilic model polymers such as hydroxypropyl methylcellulose and polyvinylpyrrolidone, was investigated, revealing that the formation of mixed BA/polymer aggregates occurs in the mixtures, which could significantly affect the drug solubilization in the gut when hydrophilic polymers are used as dispersant.

9. Self-Assembly of Natural and Chemically Modified BAs

BA salts, here simply referred to as BAs, are soluble in water and provide self-assembly. Unlike conventional surfactants with the typical head–tail amphiphilic structure these salts have a rigid molecular structure with, in the majority of the cases, a well-defined facial amphiphilicity, resulting in a more complex self-assembly. As a matter of fact, it is well established that aggregation of BAs is driven by the interplay of hydrophobic interactions and hydrogen bonds involving hydroxyl, amide and carboxylic groups and provide aggregates with merged hydrophobic and the hydrophilic domains. The issue is still debated among several self-assembly models including the stepwise mechanism from globular primary micelles to secondary elongated ones, micellar disks or helical aggregates.

In water, BAs form micelles with low aggregation number (2–20) in an associated process that is often observed to be gradual and without a sharp critical micellar concentration. Reported critical micellar concentrations decrease relative to a decrease in the number of hydroxyl groups (increasing hydrophobicity) according with the order cholate < deoxycholate, but also strongly depend on their positions and orientations with ursocholate and ursodeoxycholate that have hydroxyl groups in β-orientation presenting a lower cmc than the cholate and deoxycholate.

A decrease in the repulsions among the charged heads of deprotonated BAs can be induced by increasing the ionic strength or by decreasing the pH (for carboxylate BAs), thus promoting unidirectional growth of the micelles. Fibrils form because of the growth that can lead to gelation. For example, it is well known that DCA forms gels in water upon lowering pH around neutrality, with specific features induced by the used acid or the presence of additives. Gelation is also promoted by increasing the electrolyte concentration in DC, glycodeoxycholic (GDCA), LCA, and taurodeoxycholic (TDCA) acid salt solutions. In such gels, the chirality of the building blocks is extended also at supramolecular level where the helical structures of the fibrils, analogous to those observed in some BA crystal,, are observed.

Multivalent cations like Ca2+ can crosslink BA charge heads promoting micellar growth and gelation for cholate and GDCA. Crosslinking and formation of nanohelices can be induced on CA solution also by other multivalent cations, like those of transition metals and lanthanides. Similarly, gels can be formed by LCA upon addition of alkaline earth, lanthanide, and transition-metal ions, and by DCA in the presence of europium nitrate.

Electrolyte-induced wormlike micelle growth and gelation is also observed in lecithin/BA aqueous mixtures. A similar growth, but with a different mechanism is observed in lecithin/BA mixtures in oil, where reverse micelles of lecithin turn wormlike upon inclusion of the BAs in their interior.

The various self-assembly behavior of natural BA includes the formation of tubular aggregates, provided by LCA at strong alkaline conditions (pH = 12). It was shown by Fang and coworkers that pH variation can induce a switch of the tubules from spiral to a straight shape by changing pH. The same authors demonstrated that LCA can form ribbon-like J or tubular H aggregates when mixed with cyanine dyes, and mixed tubules with TLC that can reversibly open/close by controlling the hydration (Figure 5a).

It is important to remark that BAs are chiral molecules, and can selectively interact with enantiomers of additives both in monomeric and micellar form. This ability was reported for the interaction of monomers and micelles of DCA, GCA, and TCA with the enantiomeric conformers of bilirubin-IXa, and recently for CA and DCA with binaphthyl enantiomers. BA micellar self-assembly was extensively investigated in the past and exhaustively described in a recent review. In addition, it is worthy to stress that, in the light of the use of BAs in the formulation of drugs, the effect of active molecules on the self-assembly of BAs, as recently reported for CA and DCA in the presence of the antibiotic drug ceftriaxone, is a particularly relevant topic.

Beside the drug-conjugated derivatives employed in medicine and the polymeric molecules, a broad family of molecules can be synthesized starting from BAs, to provide an expanded set of self-assembling biomaterials. Derivatives can be prepared with dispersing ability of diverse materials like proteins or carbon nanotubes (Figure 5b). In addition, BAs can be used as substrates to prepare an ensemble of steroidal building blocks for the fabrication of unconventional supramolecular nanostructures. Typically, fibers or ribbons are formed together with more complex tubular nano- and micro-aggregates with diameters ranging from a few nanometers to half a micron. Tubules are reported to form in aqueous systems of C-3 substituted BA with various residues such as aromatic organic groups or amino acids, and sugars, often via stimuli-responsive self-assembly, triggered by pH or temperature. Interesting systems of tubules with tunable charge or diameter have been implemented by mixtures of cationic and anionic derivatives or precursor and derivative. In addition, it was recently demonstrated that BA derivative tubules are suitable elements for higher order self-assembly, providing supracolloidal non-obvious aggregates when mixed with microgels, with relevant potential in the preparation of new functional materials (Figure 5c).

Keeping the same substituent, the ability to form tubules was reported to be lost for aminoacid substituted derivatives obtained from more hydrophilic BA precursors, whereas for organic aromatic substituent, tubules with remarkably different sizes were observed to form by BA differing for number, positions and orientations of the hydroxyl groups. Spectroscopies, such as circular dichroism, show that the substituents are strongly involved in intermolecular interactions in the aggregates thereby demonstrating their relevance in the self-assembly of the derivatives. The ability to form tubules in sugar substituted derivatives is lost when glucose instead of mannose is used as substituent, thereby remarking the key role of the substituent and its specific interactions in the aggregation. Recently, selectively C-3 and C-12 substituted CA derivatives were investigated, highlighting crucial effects of position and orientation of the substituent on the self-assembly: both systems showed thermoresponsive assembly at similar critical temperature, probably due to the nature of the substituent, but involving morphologically different structures according to the position and stereochemistry of the substituting residue (Figure 5d). Exploiting the cross-linking action of cations, stable gels of helical ribbons closed into hollow cylinders have been reported to form by calcium ions and phenylalanine substituted deoxycholate at high pH.

Several BAs functionalized at the carboxylic groups to form different species like hydrazide and aminoacid esters and conjugate have also been widely investigated for their organo- or hydro-gelation properties. The importance of the hydrophobic/hydrophilic balance of the derivatives on their gelation ability was clearly illustrated. Very interestingly, the gelling ability enhancement in the mixture of cationic and anionic derivatives has also been disclosed highlighting the relevant contribution to the gelation of electrostatic attraction between the derivatives charge heads.

10. Conclusions

BAs are natural molecules ubiquitously found in vertebrates. In humans, they are produced in the hepatocytes from cholesterol modification and, through a cyclic path named enterohepatic circulation, are transported from liver to intestine, lately being transferred to the blood stream by which they are re-absorbed from the liver. The unusual amphiphilic structures allow BAs to exhibit detergent functions towards different compounds, e.g., solubilization of cholesterol, fat dietary lipids and penetration/breaking of membranes. The latter feature, expressed towards bacteria, makes BAs important antibacterial elements that are able to regulate the strength of the gut microbiota. Furthermore, BAs work in the body as hormones, being signaling molecules for the expression of genes and regulators of different metabolic paths. The physiological roles of BAs briefly summarized here and comprehensively overviewed by other specialist reports, opened the field for an extensive investigation of BAs and BADs use in biomedical applications including antimicrobics, anti-cholesterol drugs, regulator of dietary lipid uptake and drug carriers in co-formulations with other molecules (e.g., lipids and polymers). The application possibilities broaden even more when adopting BADs. BADs have been shown to be suitable building blocks for self-assembly structures showing a wide range of properties (e.g., gelling ability, stimuli responsiveness, self-healing). Such aggregates have been reported to be useful both in biological fields and material science. These aspects are going continuously growing, opening up unexpected scenarios in the preparation of different kinds of organic and inorganic nanomaterials.

References 214

  1. 1.

    Thomas C., Pellicciari R., Pruzanski M., Auwerx J., Schoonjans K. Targeting Bile-Acid Signalling for Metabolic Diseases. Nat. Rev. Drug Discov. 2008;7:678-693.

    Not in our library10.1038/nrd2619

  2. 2.

    Barbier O., Trottier J., Kaeding J., Caron P., Verreault M. Lipid-Activated Transcription Factors Control Bile Acid Glucuronidation. Mol. Cell. Biochem. 2009;326:3-8.

    Not in our library10.1007/s11010-008-0001-5

  3. 3.

    Kuhajda K., Kandrac J., Kevresan S., Mikov M., Fawcett J.P. Structure and Origin of Bile Acids: An Overview. Eur. J. Drug Metab. Pharm. 2006;31:135-143.

    Not in our library10.1007/bf03190710

  4. 4.

    Madenci D., Egelhaaf S.U. Self-Assembly in Aqueous Bile Salt Solution. Curr. Opin. Colloid Interface Sci. 2010;15:109-115.

    Not in our library10.1016/j.cocis.2009.11.010

  5. 5.

    Galantini L., di Gregorio M.C., Gubitosi M., Travaglini L., Vázquez J., Jover A., Meijide F., Soto V.H., Pavel N.V. Bile Salts and Derivatives: Rigid Unconventional Amphiphiles as Dispersants, Carriers and Superstructure Building Blocks. Curr. Opin. Colloid Interface Sci. 2015;20:170-182.

    Not in our library10.1016/j.cocis.2015.08.004

  6. 6.

    di Gregorio M.C., Travaglini L., Del Giudice A., Cautela J., Pavel N.V., Galantini L. Bile Salts: Natural Surfactants and Precursors of a Broad Family of Complex Amphiphiles. Langmuir. 2019;35:6803-6821.

    Not in our library10.1021/acs.langmuir.8b02657

  7. 7.

    Quinn R.A., Melnik A.V., Vrbanac A., Fu T., Patras K.A., Christy M.P., Bodai Z., Belda-Ferre P., Tripathi A., Chung L.K., et al. Global Chemical Effects of the Microbiome Include New Bile-Acid Conjugations. Nature. 2020;579:123-129.

    Not in our library10.1038/s41586-020-2047-9

  8. 8.

    Roberts M.S., Magnusson B.M., Burczynski F.J., Weiss M. Enterohepatic Circulation. Clin. Pharm. 2002;41:751-790.

    Not in our library10.2165/00003088-200241100-00005

  9. 9.
    Fifty years of advances in bile acid synthesis and metabolism · 2009
    Not checked
  10. 10.

    Goodwin B., Jones S.A., Price R.R., Watson M.A., McKee D.D., Moore L.B., Galardi C., Wilson J.G., Lewis M.C., Roth M.E., et al. A Regulatory Cascade of the Nuclear Receptors FXR, SHP-1, and LRH-1 Represses Bile Acid Biosynthesis. Mol. Cell. 2000;6:517-526.

    Not in our library10.1016/s1097-2765(00)00051-4

  11. 11.

    Lu T.T., Makishima M., Repa J.J., Schoonjans K., Kerr T.A., Auwerx J., Mangelsdorf D.J. Molecular Basis for Feedback Regulation of Bile Acid Synthesis by Nuclear Receptos. Mol. Cell. 2000;6:507-515.

    Not in our library10.1016/s1097-2765(00)00050-2

  12. 12.

    Denson L.A., Sturm E., Echevarria W., Zimmerman T.L., Makishima M., Mangelsdorf D.J., Karpen S.J. The Orphan Nuclear Receptor, Shp, Mediates Bile Acid-Induced Inhibition of the Rat Bile Acid Transporter, Ntcp. Gastroenterology. 2001;121:140-147.

    Not in our library10.1053/gast.2001.25503

  13. 13.

    Kim I., Ahn S.H., Inagaki T., Choi M., Ito S., Guo G.L., Kliewer S.A., Gonzalez F.J. Differential Regulation of Bile Acid Homeostasis by the Farnesoid X Receptor in Liver and Intestine. J. Lipid Res. 2007;48:2664-2672.

    Not in our library10.1194/jlr.m700330-jlr200

  14. 14.

    Kong B., Wang L., Chiang J.Y., Zhang Y., Klaassen C.D., Guo G.L. Mechanism of Tissue-Specific Farnesoid X Recptor in Suppressing the Expression of Genes in Bile-Acid Synthesis in Mice. Hepatology. 2012;56:1034-1043.

    Not in our library10.1002/hep.25740

  15. 15.

    Li T., Francl J.M., Boehme S., Chiang J.Y.L. Regulation of Cholesterol and Bile Acid Homeostasis by the Cholesterol 7α-Hydroxylase/Steroid Response Element-Binding Protein 2/MicroRNA-33a Axis in Mice. Hepatology. 2013;58:1111-1121.

    Not in our library10.1002/hep.26427

  16. 16.

    Meissner M., Wolters H., de Boer R.A., Havinga R., Boverhof R., Bloks V.W., Kuipers F., Groen A.K. Bile Acid Sequestration Normalizes Plasma Cholesterol and Reduces Atherosclerosis in Hypercholesterolemic Mice. No Additional Effect of Physical Activity. Atherosclerosis. 2013;228:117-123.

    Not in our library10.1016/j.atherosclerosis.2013.02.021

  17. 17.

    Mazidi M., Rezaie P., Karimi E., Kengne A.P. The effects of bile acid sequestrants on lipid profile and blood glucose concentrations: A systematic review and meta-analysis of randomized controlled trials. Int. J. Cardiol. 2017;227:850-857.

    Not in our library10.1016/j.ijcard.2016.10.011

  18. 18.

    Kuipers F., Bloks V.W., Groen A.K. Beyond intestinal soap—Bile acids in metabolic control. Nat. Rev. Endocrinol. 2014;10:488-498.

    Not in our library10.1038/nrendo.2014.60

  19. 19.

    Hou R., Goldberg A.C. Lowering Low-Density Lipoprotein Cholesterol:Statins, Ezetimibe, Bile Acid Sequestrants, and Combinations: Comparative Efficacy and Safety. Endocrinol. Metab. Clin. N. Am. 2009;38:79-97.

    Not in our library10.1016/j.ecl.2008.11.007

  20. 20.

    Sehayek E., Ono J.G., Shefer S., Nguyen L.B., Wang N., Batta A.K., Salen G., Smith J.D., Tall A.R., Breslow J.L. Biliary Cholesterol Excretion: A Novel Mechanism That Regulates Dietary Cholesterol Absorption. Proc. Natl. Acad. Sci. USA. 1998;95:10194-10199.

    Not in our library10.1073/pnas.95.17.10194

  21. 21.

    Mandeville W., Goldberg D. The Sequestration of Bile Acids, a Non-Absorbed Method for Cholesterol Reduction: A Review. Curr. Pharm. Des. 1997;3:15-28.

    Not in our library

  22. 22.

    Camilleri M., Gores G.J. Therapeutic Targeting of Bile Acids. Am. J. Physiol. Gastrointest. Liver Physiol. 2020;55905:209-215.

    Not in our library10.1152/ajpgi.00121.2015

  23. 23.

    Lundasen T., Galman C., Angelini B., Rudling M. Circulating Intestinal Fibroblast Growth Factor 19 Has a Pronounced Diurnal Variation and Modulates Hepatic Bile Acid Synthesis in Man. J. Intern. Med. 2006;260:530-536.

    Not in our library10.1111/j.1365-2796.2006.01731.x

  24. 24.

    Walters J.R.F., Tasleem A.L.I.M., Omer O.S., Brydon W.G., Dew T., Roux C.W.L.E. A New Mechanism for Bile Acid Diarrhea: Defective Feedback Inhibition of Bile Acid Biosynthesis. Clin. Gastroenterol. Hepatol. 2009;7:1189-1194.

    Not in our library10.1016/j.cgh.2009.04.024

  25. 25.

    Johnston I., Nolan J., Pattni S.S., Walters J.R.F. New Insights into Bile Acid Malabsorption. Curr. Gastroenterol. Rep. 2011;13:418-425.

    Not in our library10.1007/s11894-011-0219-3

  26. 26.

    Walters J.R.F. Bile Acid Diarrhoea and FGF19: New Views. Nat. Rev. Gastroenterol. Hepatol. 2014;11:426-434.

    Not in our library10.1038/nrgastro.2014.32

  27. 27.

    Hofmann A.F., Mysels K.J. Bile Salts as Biological Surfactants. Colloids Surf. 1988;30:145-173.

    Not in our library10.1016/0166-6622(87)80207-x

  28. 28.

    Huval C.C., Holmes-Farley S.R., Mandeville W.H., Sacchiero R., Dhal P.K. Syntheses of Hydrophobically Modified Cationic Hydrogels by Copolymerization of Alkyl Substituted Diallylamine Monomers and Their Use as Bile Acid Sequestrants. Eur. Polym. J. 2004;40:693-701.

    Not in our library10.1016/j.eurpolymj.2003.11.012

  29. 29.

    Wilcox C., Turner J., Green J. Systematic Review: The Management of Chronic Diarrhoea Due to Bile Acid Malabsorption. Aliment. Pharm. Ther. 2014;39:923-939.

    Not in our library10.1111/apt.12684

  30. 30.

    Hansen M., Sonne D.P., Knop F.K. Bile Acid Sequestrants: Glucose-Lowering Mechanisms and Efficacy in Type 2 Diabetes. Curr. Diab. Rep. 2014;14:482.

    Not in our library10.1007/s11892-014-0482-4

  31. 31.

    Seetharam P., Rodrigues G. Short Bowel Syndrome: A Review of Management Options. Saudi J. Gastroenterol. 2011;17:229-235.

    Not in our library10.4103/1319-3767.82573

  32. 32.

    Emmett M., Guirl M.J., Santa Ana C.A., Porter J.L., Neimark S., Hofmann A.F., Fordtran J.S. Conjugated Bile Acid Replacement Therapy Reduces Urinary Oxalate Excretion in Short Bowel Syndrome. Am. J. Kidney Dis. 2003;41:230-237.

    Not in our library10.1053/ajkd.2003.50012

  33. 33.

    Gruy-Kapral C., Little K.H., Fordtran J.S., Meziere T.L., Hagey L.R., Hofmann A.F. Conjugated Bile ACid Replacement Theraphy for Short-Bowel Syndrome. Gastroenterology. 1999;116:15-21.

    Not in our library10.1016/s0016-5085(99)70223-4

  34. 34.

    Van de Heijning B.J.M., Stolk M.F.J., Van Erpecum K.J., Renooij W., Groen A.K., VanBerge-Henegouwen G.P. Bile Salt-Induced Cholesterol Crystal Formation from Model Bile Vesicles: A Time Course Study. J. Lipid Res. 1994;35:1002-1011.

    Not in our library10.1016/s0022-2275(20)40097-5

  35. 35.

    Tamesue N., Juniper K. Concentrations of Bile Salts at the Critical Micellar Concentration of Human Gall Bladder Bile. Gastroenterology. 1967;52:473-479.

    Not in our library10.1016/s0016-5085(67)80173-2

  36. 36.

    Higuchi W.I., Tzeng C.S., Chang S.J., Chiang H.J., Liu C.L. Estimation of Cholesterol Solubilization by a Mixed Micelle Binding Model in Aqueous Tauroursodeoxycholate:Lecithin:Cholesterol Solutions. J. Pharm. Sci. 2008;97:340-349.

    Not in our library10.1002/jps.21096

  37. 37.

    Reynier M.O., Montet J.C., Gerolami A., Marteau C., Crotte C., Montet A.M., Mathieu S. Comparative Effects of Cholic, Chenodeoxycholic, and Ursodeoxycholic Acids on Micellar Solubilization and Intestinal Absorption of Cholesterol. J. Lipid Res. 1981;22:467-473.

    Not in our library10.1016/s0022-2275(20)34961-0

  38. 38.

    Rudling M., Laskar A., Straniero S. Gallbladder Bile Supersaturated with Cholesterol in Gallstone Patients Preferentially Develops from Shortage of Bile Acids. J. Lipid Res. 2019;60:498-505.

    Not in our library10.1194/jlr.s091199

  39. 39.

    Carey M.C., Small D.M. The Physical Chemistry of Cholesterol Solubility in Bile. Relationship to Gallstone Formation and Dissolution in Man. J. Clin. Investig. 1978;61:998-1026.

    Not in our library10.1172/jci109025

  40. 40.

    Coreta-Gomes F.M., Vaz W.L.C., Wasielewski E., Geraldes C.F.G., Moreno M.J. Quantification of Cholesterol Solubilized in Dietary Micelles: Dependence on Human Bile Salt Variability and the Presence of Dietary Food Ingredients. Langmuir. 2016;32:4564-4574.

    Not in our library10.1021/acs.langmuir.6b00723

  41. 41.

    Portincasa P. Therapy of Gallstone Disease: What It Was, What It Is, What It Will Be. World J. Gastrointest. Pharm. Ther. 2012;3:7-20.

    Not in our library10.4292/wjgpt.v3.i2.7

  42. 42.

    Jang S.I., Fang S., Kim K.P., Ko Y., Kim H., Oh J., Hong G.Y., Lee S.Y., Kim J.M., Noh I., et al. Combination Treatment with N-3 Polyunsaturated Fatty Acids and Ursodeoxycholic Acid Dissolves Cholesterol Gallstones in Mice. Sci. Rep. 2019;9:1-13.

    Not in our library10.1038/s41598-019-49095-z

  43. 43.

    Boyer J.L. Bile Formation and Secretion. Compr. Physiol. 2013;3:1035-1078.

    Not in our library10.1002/cphy.c120027

  44. 44.

    Funabashi M., Grove T.L., Wang M., Varma Y., McFadden M.E., Brown L.C., Guo C., Higginbottom S., Almo S.C., Fischbach M.A. A Metabolic Pathway for Bile Acid Dehydroxylation by the Gut Microbiome. Nature. 2020;582:566-570.

    Not in our library10.1038/s41586-020-2396-4

  45. 45.

    Maldonado-Valderrama J., Wilde P., MacIerzanka A., MacKie A. The Role of Bile Salts in Digestion. Adv. Colloid Interface Sci. 2011;165:36-46.

    Not in our library10.1016/j.cis.2010.12.002

  46. 46.

    Macierzanka A., Torcello-Gómez A., Jungnickel C., Maldonado-Valderrama J. Bile Salts in Digestion and Transport of Lipids. Adv. Colloid Interface Sci. 2019;274:102045.

    Not in our library10.1016/j.cis.2019.102045

  47. 47.

    Naso J.N., Bellesi F.A., Pizones Ruiz-Henestrosa V.M., Pilosof A.M.R. Studies on the Interactions between Bile Salts and Food Emulsifiers under in Vitro Duodenal Digestion Conditions to Evaluate Their Bile Salt Binding Potential. Colloids Surf. B. 2019;174:493-500.

    Not in our library10.1016/j.colsurfb.2018.11.024

  48. 48.

    Cremers C.M., Knoefler D., Vitvitsky V., Banerjee R., Jakob U. Bile Salts Act as Effective Protein-Unfolding Agents and Instigators of Disulfide Stress in Vivo. Proc. Natl. Acad. Sci. USA. 2014;111:E1610-E1619.

    Not in our library10.1073/pnas.1401941111

  49. 49.

    Pabois O., Lorenz C.D., Harvey R.D., Grillo I., Grundy M.M.L., Wilde P.J., Gerelli Y., Dreiss C.A. Molecular Insights into the Behaviour of Bile Salts at Interfaces: A Key to Their Role in Lipid Digestion. J. Colloid Interface Sci. 2019;556:266-277.

    Not in our library10.1016/j.jcis.2019.08.010

  50. 50.
    Absorption-Enhancing Effects of Bile Salts · 2015
    No notice
  51. 51.

    Naumann S., Schweiggert-Weisz U., Eglmeier J., Haller D., Eisner P. In Vitro Interactions of Dietary Fibre Enriched Food Ingredients with Primary and Secondary Bile Acids. Nutrients. 2019;11:1424.

    Not in our library10.3390/nu11061424

  52. 52.

    Shokry D.S., Waters L.J., Parkes G.M.B., Mitchell J.C., Snowden M.J. Formation of a Bile Salt-Drug Hydrogel to Predict Human Intestinal Absorption. J. Pharm. Sci. 2019;108:279-287.

    Not in our library10.1016/j.xphs.2018.10.005

  53. 53.

    Torcello-Gómez A., Maldonado-Valderrama J., Martín-Rodríguez A., McClements D.J. Physicochemical Properties and Digestibility of Emulsified Lipids in Simulated Intestinal Fluids: Influence of Interfacial Characteristics. Soft Matter. 2011;7:6167-6177.

    Not in our library10.1039/c1sm05322a

  54. 54.

    Hofmann A.F., Eckmann L. How Bile Acids Confer Gut Mucosal Protection against Bacteria. Proc. Natl. Acad. Sci. USA. 2006;103:4333-4334.

    Not in our library10.1073/pnas.0600780103

  55. 55.

    Begley M., Gahan C.G.M., Hill C. The Interaction between Bacteria and Bile. FEMS Microbiol. Rev. 2005;29:625-651.

    Not in our library10.1016/j.femsre.2004.09.003

  56. 56.

    Pazzi P., Puviani A.C., Libera M.D., Guerra G., Ricci D., Gullini S., Ottolenghi C. Bile Salt-Induced Cytotoxicity and Ursodeoxycholate Cytoprotection: In-Vitro Study in Perifused Rat Hepatocytes. Eur. J. Gastroenterol. Hepatol. 1997;9:703-709.

    Not in our library10.1097/00042737-199707000-00011

  57. 57.

    Sung J.Y., Shaffer E.A., Costerton J.W. Antibacterial Activity of Bile Salts against Common Biliary Pathogens—Effects of Hydrophobicity of the Molecule and in the Presence of Phospholipids. Dig. Dis. Sci. 1993;38:2104-2112.

    Not in our library10.1007/bf01297092

  58. 58.

    Leverrier P., Dimova D., Pichereau V., Auffray Y., Boyaval P., Jan G. Susceptibility and Adaptive Response to Bile Salts in Propionibacterium Freudenreichii: Physiological and Proteomic Anlysis. Appl. Environ. Microbiol. 2003;69:3809-3818.

    Not in our library10.1128/aem.69.7.3809-3818.2003

  59. 59.

    Fujisawa T., Mori M. Influence of Various Bile Salts on β-Glucuronidase Activity of Intestinal Bacteria. Lett. Appl. Microbiol. 1997;25:95-97.

    Not in our library10.1046/j.1472-765x.1997.00180.x

  60. 60.

    Coleman R., Lowe P.J., Billington D. Membrane Lipid Composition and Susceptibility to Bile Salt Damage. BBA Biomembr. 1980;599:294-300.

    Not in our library10.1016/0005-2736(80)90075-9

  61. 61.

    Kociubinski G., Gómez Zavaglia A., Pérez P.F., Disalvo E.A., De Antoni G.L. Effect of Bile Components on the Surface Properties of Bifidobacteria. J. Dairy Res. 2002;69:293-302.

    Not in our library10.1017/s0022029901005313

  62. 62.

    Tian Y., Gui W., Koo I., Smith P.B., Allman E.L., Nichols R.G., Rimal B., Cai J., Liu Q., Patterson A.D. The Microbiome Modulating Activity of Bile Acids. Gut Microbes. 2020;11:979-996.

    Not in our library10.1080/19490976.2020.1732268

  63. 63.

    Small D.M., Lilly H.S., Hamilton J.A., Cabral D.J. Transbilayer Movement of Bile Acids in Model Membranes. Biochemistry. 1987;26:1801-1804.

    Not in our library10.1021/bi00381a002

  64. 64.

    Inagaki T., Moschetta A., Lee Y.K., Peng L., Zhao G., Downes M., Yu R.T., Shelton J.M., Richardson J.A., Repa J.J., et al. Regulation of Antibacterial Defense in the Small Intestine by the Nuclear Bile Acid Receptor. Proc. Natl. Acad. Sci. USA. 2006;103:3920-3925.

    Not in our library10.1073/pnas.0509592103

  65. 65.

    Kang J.D., Myers C.J., Harris S.C., Kakiyama G., Lee I.K., Yun B.S., Matsuzaki K., Furukawa M., Min H.K., Bajaj J.S., et al. Bile Acid 7α-Dehydroxylating Gut Bacteria Secrete Antibiotics That Inhibit Clostridium Difficile: Role of Secondary Bile Acids. Cell Chem. Biol. 2019;26:27-34.

    Not in our library10.1016/j.chembiol.2018.10.003

  66. 66.

    Ma C., Han M., Heinrich B., Fu Q., Zhang Q., Sandhu M., Agdashian D., Terabe M., Berzofsky J.A., Fako V., et al. Gut Microbiome–Mediated Bile Acid Metabolism Regulates Liver Cancer via NKT Cells. Science. 2018;360:eaan5931.

    Not in our library10.1126/science.aan5931

  67. 67.

    Mao J., Chen X., Wang C., Li W., Li J. Effects and Mechanism of the Bile Acid (Farnesoid X) Receptor on the Wnt/β-Catenin Signaling Pathway in Colon Cancer. Oncol. Lett. 2020;20:337-345.

    Not in our library10.3892/ol.2020.11545

  68. 68.

    Di Ciaula A., Wang D.Q.H., Molina E.M., Baccetto R.L., Calamita G., Palmieri V.O., Portincasa P. Bile Acids and Cancer: Direct and Environmental-Dependent Effects. Ann. Hepatol. 2017;16:S87-S105.

    Not in our library10.5604/01.3001.0010.5501

  69. 69.
    Bile Acids and Their Derivatives as Potential Modifiers of Drug Release and Pharmacokinetic Profiles · 2018
    No notice
  70. 70.

    Wang D.Q.H., Carey M.C. Therapeutic Uses of Animal Biles in Traditional Chinese Medicine: An Ethnopharmacological, Biophysical Chemical and Medicinal Review. World J. Gastroenterol. 2014;20:9952-9975.

    Not in our library10.3748/wjg.v20.i29.9952

  71. 71.

    Goldberg A.A., Beach A., Davies G.F., Harkness T.A.A., LeBlanc A., Titorenko V.I. Lithocholic Bile Acid Selectively Kills Neuroblastoma Cells, While Sparing Normal Neuronal Cells. Oncotarget. 2011;2:761-782.

    Not in our library10.18632/oncotarget.338

  72. 72.

    Luu T.H., Bard J.M., Carbonnelle D., Chaillou C., Huvelin J.M., Bobin-Dubigeon C., Nazih H. Lithocholic Bile Acid Inhibits Lipogenesis and Induces Apoptosis in Breast Cancer Cells. Cell. Oncol. 2018;41:13-24.

    Not in our library10.1007/s13402-017-0353-5

  73. 73.

    Goldberg A.A., Titorenko V.I., Beach A., Thomas Sanderson J. Bile Acids Induce Apoptosis Selectively in Androgen-Dependent and -Independent Prostate Cancer Cells. PeerJ. 2013;1:e122.

    Not in our library10.7717/peerj.122

  74. 74.

    Trah J., Arand J., Oh J., Pagerols-Raluy L., Trochimiuk M., Appl B., Heidelbach H., Vincent D., Saleem M.A., Reinshagen K., et al. Lithocholic Bile Acid Induces Apoptosis in Human Nephroblastoma Cells: A Non-Selective Treatment Option. Sci. Rep. 2020;10:1-8.

    Not in our library10.1038/s41598-020-77436-w

  75. 75.

    Goossens J.F., Bailly C. Ursodeoxycholic Acid and Cancer: From Chemoprevention to Chemotherapy. Pharm. Ther. 2019;203:107396.

    Not in our library10.1016/j.pharmthera.2019.107396

  76. 76.

    Blanchet M., Brunel J.M. Bile Acid Derivatives: From Old Molecules to a New Potent Therapeutic Use: An Overview. Curr. Med. 2018;25:3613-3636.

    Not in our library10.2174/0929867325666180309113737

  77. 77.

    Suh H., Jung E.J., Kim T.H., Lee H.Y., Park Y.H., Kim K.W. Anti-angiogenic activity of ursodeoxycholic acid and its derivatives. Cancer Lett. 1997;113:117-122.

    Not in our library10.1016/s0304-3835(97)04604-1

  78. 78.

    Liu H., Qin C.K., Han G.Q., Xu H.W., Ren W.H., Qin C.Y. Synthetic chenodeoxycholic acid derivative, HS-1200, induces apoptosis of human hepatoma cells via a mitochondrial pathway. Cancer Lett. 2008;270:242-249.

    Not in our library10.1016/j.canlet.2008.05.014

  79. 79.

    Park S.E., Lee S.W., Hossain M.A., Kim M.Y., Kim M.N., Ahn E.Y., Park Y.C., Suh H., Kim G.Y., Choi Y.H., et al. A chenodeoxycholic derivative, HS-1200, induces apoptosis and cell cycle modulation via Egr-1 gene expression control on human hepatoma cells. Cancer Lett. 2008;270:77-86.

    Not in our library10.1016/j.canlet.2008.04.038

  80. 80.

    Im E., Choi Y.H., Paik K.J., Suh H., Jin Y., Kim K.W., Yoo Y.H., Kim N.D. Novel bile acid derivatives induce apoptosis via a p53-independent pathway in human breast carcinoma cells. Cancer Lett. 2001;163:83-93.

    Not in our library10.1016/s0304-3835(00)00671-6

  81. 81.

    Im E.-O., Lee S., Suh H., Kim K.-W., Bae Y.T., Kim N.D. A novel ursodeoxycholic acid derivative induces apoptosis in human MCF-7 breast cancer cells. Pharm. Pharmacol. Commun. 1999;5:293-298.

    Not in our library10.1211/146080899128734875

  82. 82.

    Kim N.D., Im E.-O., Hyun Yoo Y., Hyun Choi Y. Modulation of the cell cycle and induction of apoptosis in human cancer cells by synthetic bile acids. Curr. Cancer Drug Targets. 2006;6:681-689.

    Not in our library10.2174/156800906779010236

  83. 83.

    Choi Y.H., Im E.O., Suh H., Jin Y., Yoo Y.H., Kim N.D. Apoptosis and modulation of cell cycle control by synthetic derivatives of ursodeoxycholic acid and chenodeoxycholic acid in human prostate cancer cells. Cancer Lett. 2003;199:157-167.

    Not in our library10.1016/s0304-3835(03)00351-3

  84. 84.

    Park S., Choi H.J., Yee S.B., Chung H.Y., Suh H., Choi Y.H., Yoo Y.H., Kim N.D. Synthetic bile acid derivatives inhibit cell proliferation and induce apoptosis in HT-29 human colon cancer cells. Int. J. Oncol. 2004;25:231-236.

    Not in our library10.3892/ijo.25.1.231

  85. 85.

    Brossard D., El Kihal L., Clément M., Sebbahi W., Khalid M., Roussakis C., Rault S. Synthesis of bile acid derivatives and in vitro cytotoxic activity with pro-apoptotic process on multiple myeloma (KMS-11), glioblastoma multiforme (GBM), and colonic carcinoma (HCT-116) human cell lines. Eur. J. Med. Chem. 2010;45:2912-2918.

    Not in our library10.1016/j.ejmech.2010.03.016

  86. 86.

    Park K., Kim Y.S., Lee G.Y., Nam J.O., Lee S.K., Park R.W., Kim S.Y., Kim I.S., Byun Y. Antiangiogenic effect of bile acid acylated heparin derivative. Pharm. Res. 2006;24:176-185.

    Not in our library10.1007/s11095-006-9139-6

  87. 87.

    Park K., Lee S.K., Son D.H., Park S.A., Kim K., Chang H.W., Jeong E.J., Park R.W., Kim I.S., Kwon I.C., et al. The attenuation of experimental lung metastasis by a bile acid acylated-heparin derivative. Biomaterials. 2007;28:2667-2676.

    Not in our library10.1016/j.biomaterials.2007.02.001

  88. 88.

    Singh M., Singh A., Kundu S., Bansal S., Bajaj A. Deciphering the role of charge, hydration, and hydrophobicity for cytotoxic activities and membrane interactions of bile acid based facial amphiphiles. Biochim. Biophys. Acta Biomembr. 2013;1828:1926-1937.

    Not in our library10.1016/j.bbamem.2013.04.003

  89. 89.

    Agarwal D.S., Shilpa Anantaraju H., Sriram D., Yogees-wari P., Nanjegowda S.H., Mallu P., Sakhuja R. Synthesis, characterization and biological evaluation of bile acid-aromatic/heteroaromatic amides linked via amino acids as anti-cancer agents. Steroids. 2016;107:87-97.

    Not in our library10.1016/j.steroids.2015.12.022

  90. 90.

    Marchesi E., Chinaglia N., Capobianco M.L., Marchetti P., Huang T.E., Weng H.C., Guh J.H., Hsu L.C., Perrone D., Navacchia M.L. Dihydroartemisinin–Bile Acid Hybridization as an Effective Approach to Enhance Dihydroartemisinin Anticancer Activity. ChemMedChem. 2019;14:779-787.

    Not in our library10.1002/cmdc.201800756

  91. 91.
    Evaluation of the Anticancer Activity of a Bile Acid-Dihydroartemisinin Hybrid Ursodeoxycholic-Dihydroartemisinin in Hepatocellular Carcinoma Cells · 2020
    Not checked
  92. 92.
    Enhanced Liver Targeting of Camptothecin via Conjugation with Deoxycholic Acid · 2019
    Not checked
  93. 93.

    Navacchia M.L., Marchesi E., Mari L., Chinaglia N., Gallerani E., Gavioli R., Capobianco M.L., Perrone D. Rational Design of Nucleoside-Bile Acid Conjugates Incorporating a Triazole Moiety for Anticancer Evaluation and SAR Exploration. Molecules. 2017;22:1710.

    Not in our library10.3390/molecules22101710

  94. 94.

    Seroka B., Łotowski Z., Hryniewicka A., Rárová L., Sicinski R.R., Tomkiel A.M., Morzycki J.W. Synthesis of New Cisplatin Derivatives from Bile Acids. Molecules. 2020;25:655.

    Not in our library10.3390/molecules25030655

  95. 95.

    Navacchia M.L., Fraix A., Chinaglia N., Gallerani E., Perrone D., Cardile V., Graziano A.C.E., Capobianco M.L., Sortino S. NO Photoreleaser-Deoxyadenosine and -Bile Acid Derivative Bioconjugates as Novel Potential Photochemotherapeutics. ACS Med. Chem. Lett. 2016;7:939-943.

    Not in our library10.1021/acsmedchemlett.6b00257

  96. 96.

    Salomatina O.V., Popadyuk I.I., Zakharenko A.L., Olga D., Chepanova A.A., Dyrkheeva N.S., Komarova N.I., Reynisson J., Anarbaev R.O., Salakhutdinov N.F., et al. Deoxycholic Acid as a Molecular Scaffold for Tyrosyl-DNA Phosphodiesterase 1 Inhibition: A Synthesis, Structure-Activity Relationship and Molecular Modeling Study. Steroids. 2020;165:108771.

    Not in our library10.1016/j.steroids.2020.108771

  97. 97.

    Salomatina O.V., Popadyuk I.I., Zakharenko A.L., Zakharova O.D., Fadeev D.S., Komarova N.I., Reynisson J., Arabshahi H.J., Chand R., Volcho K.P., et al. Novel Semisynthetic Derivatives of Bile Acids as Effective Tyrosyl-DNA Phosphodiesterase 1 Inhibitors. Molecules. 2018;23:679.

    Not in our library10.3390/molecules23030679

  98. 98.

    Schölmerich J., Becher M.-S., Schmidt K., Schubert R., Kremer B., Feldhaus S., Gerok W. Influence of Hydroxylation and Conjugation of Bile Salts on Their Membrane-Damaging Properties-Studies on Isolated Hepatocytes and Lipid Membrane Vesicles. Hepatology. 1984;4:661-666.

    Not in our library10.1002/hep.1840040416

  99. 99.
    In Vitro Antibacterial Activity of Unconjugated and Conjugated Bile Salts on Staphylococcus aureus · 2017
    No notice
  100. 100.

    Neves A.R., Almeida J.R., Carvalhal F., Câmara A., Pereira S., Antunes J., Vasconcelos V., Pinto M., Silva E.R., Sousa E., et al. Overcoming Environmental Problems of Biocides: Synthetic Bile Acid Derivatives as a Sustainable Alternative. Ecotoxicol. Environ. Saf. 2020;187:109812.

    Not in our library10.1016/j.ecoenv.2019.109812

  101. 101.

    Guan Q., Li C., Schmidt E.J., Boswell J.S., Walsh J.P., Allman G.W., Savage P.B. Preparation and Characterization of Cholic Acid-Derived Antimicrobial Agents with Controlled Stabilities. Org. Lett. 2000;2:2837-2840.

    Not in our library10.1021/ol0062704

  102. 102.

    Ding B., Guan Q., Walsh J.P., Boswell J.S., Winter T.W., Winter E.S., Boyd S.S., Li C., Savage P.B. Correlation of the Antibacterial Activities of Cationic Peptide Antibiotics and Cationic Steroid Antibiotics. J. Med. Chem. 2002;45:663-669.

    Not in our library10.1021/jm0105070

  103. 103.

    Savage P.B., Li C., Taotafa U., Ding B., Guan Q. Antibacterial Properties of Cationic Steroid Antibiotics. FEMS Microbiol. Lett. 2002;217:1-7.

    Not in our library10.1111/j.1574-6968.2002.tb11448.x

  104. 104.

    Rahman M.A., Sha Y., Jui M.S., Lamm M.E., Ma Y., Tang C. Facial Amphiphilicity-Induced Self-Assembly (FAISA) of Amphiphilic Copolymers. Macromolecules. 2019;52:9526-9535.

    Not in our library10.1021/acs.macromol.9b02008

  105. 105.

    Rahman M.A., Jui M.S., Bam M., Cha Y., Luat E., Alabresm A., Nagarkatti M., Decho A.W., Tang C. Facial Amphiphilicity-Induced Polymer Nanostructures for Antimicrobial Applications. ACS Appl. Mater. Interfaces. 2020;12:21221-21230.

    Not in our library10.1021/acsami.9b19712

  106. 106.

    Rahman M.A., Bam M., Luat E., Jui M.S., Ganewatta M.S., Shokfai T., Nagarkatti M., Decho A.W., Tang C. Macromolecular-Clustered Facial Amphiphilic Antimicrobials. Nat. Commun. 2018;9:1-10.

    Not in our library10.1038/s41467-018-07651-7

  107. 107.

    Kramer W., Glombik H. Bile Acid Reabsorption Inhibitors (BARI): Novel Hypolipidemic Drugs. Curr. Med. Chem. 2006;13:997-1016.

    Not in our library10.2174/092986706776361003

  108. 108.

    Tolle-Sander S., Lentz K.A., Maeda D.Y., Coop A., Polli J.E. Increased Acyclovir Oral Bioavailability via a Bile Acid Conjugate. Mol. Pharm. 2004;1:40-48.

    Not in our library10.1021/mp034010t

  109. 109.

    Jha S.K., Chung J.Y., Pangeni R., Choi H.S., Subedi L., Kweon S., Choi J.U., Byun Y., Kim Y.H., Park J.W. Enhanced Antitumor Efficacy of Bile Acid-Lipid Complex-Anchored Docetaxel Nanoemulsion via Oral Metronomic Scheduling. J. Control. Release. 2020;328:368-394.

    Not in our library10.1016/j.jconrel.2020.08.067

  110. 110.
    Exploitation of Bile Acid Transport Systems in Prodrug Design · 2007
    Not checked
  111. 111.

    Kramer W. Transporters, Trojan Horses and Therapeutics: Suitability of Bile Acid and Peptide Transporters for Drug Delivery. Biol. Chem. 2011;392:77-94.

    Not in our library10.1515/bc.2011.017

  112. 112.

    Subramanian S., Iles T., Ikramuddin S., Steer C.J. Merit of an Ursodeoxycholic Acid Clinical Trial in COVID-19 Patients. Vaccines. 2020;8:320.

    Not in our library10.3390/vaccines8020320

  113. 113.

    Carino A., Moraca F., Fiorillo B., Marchianò S., Sepe V., Biagioli M., Finamore C., Bozza S., Francisci D., Distrutti E., et al. Hijacking SARS-CoV-2/ACE2 Receptor Interaction by Natural and Semi-Synthetic Steroidal Agents Acting on Functional Pockets on the Receptor Binding Domain. Front. Chem. 2020;8:1-15.

    Not in our library10.3389/fchem.2020.572885

  114. 114.

    Zhao Y., Cho H., Widanapathirana L., Zhang S. Conformationally Controlled Oligocholate Membrane Transporters: Learning through Water Play. Acc. Chem. Res. 2013;28:2763-2772.

    Not in our library10.1021/ar300337f

  115. 115.

    Le Dévédec F., Fuentealba D., Strandman S., Bohne C., Zhu X.X. Aggregation Behavior of Pegylated Bile Acid Derivatives. Langmuir. 2012;28:13431-13440.

    Not in our library10.1021/la303218q

  116. 116.

    Giguère G., Zhu X.X. Functional Star Polymers with a Cholic Acid Core and Their Thermosensitive Properties. Biomacromolecules. 2010;11:201-206.

    Not in our library10.1021/bm9010694

  117. 117.

    Despa F., Luo J.T., Li J., Duan Y., Lam K.S. Cholic Acid Micelles—Controlling the Size of the Aqueous Cavity by PEGylation. Phys. Chem. Chem. Phys. 2010;12:1589-1594.

    Not in our library10.1039/b914440d

  118. 118.

    Cunningham A.J., Robinson M., Banquy X., Leblond J., Zhu X.X. Bile Acid-Based Drug Delivery Systems for Enhanced Doxorubicin Encapsulation: Comparing Hydrophobic and Ionic Interactions in Drug Loading and Release. Mol. Pharm. 2018;15:1266-1276.

    Not in our library10.1021/acs.molpharmaceut.7b01091

  119. 119.

    Pal S., Ghosh Roy S., De P. Synthesis via RAFT Polymerization of Thermo- and PH-Responsive Random Copolymers Containing Cholic Acid Moieties and Their Self-Assembly in Water. Polym. Chem. 2014;5:1275-1284.

    Not in our library10.1039/c3py01317k

  120. 120.

    Jia Y.G., Zhu X.X. Self-Healing Supramolecular Hydrogel Made of Polymers Bearing Cholic Acid and β-Cyclodextrin Pendants. Chem. Mater. 2015;27:387-393.

    Not in our library10.1021/cm5041584

  121. 121.

    Shao Y., Jia Y.G., Shi C., Luo J., Zhu X.X. Block and Random Copolymers Bearing Cholic Acid and Oligo(Ethylene Glycol) Pendant Groups: Aggregation, Thermosensitivity, and Drug Loading. Biomacromolecules. 2014;15:1837-1844.

    Not in our library10.1021/bm5002262

  122. 122.

    Du J., Tang Y., Lewis A.L., Armes S.P. PH-Sensitive Vesicles Based on a Biocompatible Zwitterionic Diblock Copolymer. J. Am. Chem. Soc. 2005;127:17982-17983.

    Not in our library10.1021/ja056514l

  123. 123.

    Xiong Y., Qi J., Yao P. Amphiphilic Cholic-Acid-Modified Dextran Sulfate and Its Application for the Controlled Delivery of Superoxide Dismutase. Macromol. Biosci. 2012;12:515-524.

    Not in our library10.1002/mabi.201100367

  124. 124.

    Ahlheirn M., Hallensleben M.L. Kondensationspolymerisation von Gallensäuren Herrn. 1988, 9, 299–302. Macromol. Rapid Commun. 1988;9:299-302.

    Not in our library

  125. 125.

    Shao Y., Lavigueur C., Zhu X.X. Multishape Memory Effect of Norbornene-Based Copolymers with Cholic Acid Pendant Groups. Macromolecules. 2012;45:1924-1930.

    Not in our library10.1021/ma202506b

  126. 126.

    Zhang K., Jia Y.G., Tsai I.H., Strandman S., Ren L., Hong L., Zhang G., Guan Y., Zhang Y., Zhu X.X. “Bitter-Sweet” Polymeric Micelles Formed by Block Copolymers from Glucosamine and Cholic Acid. Biomacromolecules. 2017;18:778-786.

    Not in our library10.1021/acs.biomac.6b01640

  127. 127.

    Nichifor M., Stanciu M.C., Doroftei F. Self-Assembly of Dextran–b–Deoxycholic Acid Polyester Copolymers: Copolymer Composition and Self-Assembly Procedure Tune the Aggregate Size and Morphology. Carbohydr. Polym. 2021;252:117147.

    Not in our library10.1016/j.carbpol.2020.117147

  128. 128.

    Stojančević M., Pavlović N., Goločorbin-Kon S., Mikov M. Application of Bile Acids in Drug Formulation and Delivery. Front. Life Sci. 2013;7:112-122.

    Not in our library10.1080/21553769.2013.879925

  129. 129.

    Damgé C.P., Maincent P. Nanoparticles Strategies for the Oral Delivery of Insulin. Expert Opin. Drug Deliv. 2008;5:45-68.

    Not in our library10.1517/17425247.5.1.45

  130. 130.

    Al-Mahallawi A.M., Abdelbary A.A., Aburahma M.H. Investigating the Potential of Employing Bilosomes as a Novel Vesicular Carrier for Transdermal Delivery of Tenoxicam. Int. J. Pharm. 2015;485:329-340.

    Not in our library10.1016/j.ijpharm.2015.03.033

  131. 131.

    Mendonça P.V., Serra A.C., Silva C.L., Simões S., Coelho J.F.J. Polymeric Bile Acid Sequestrants—Synthesis Using Conventional Methods and New Approaches Based on “Controlled”/Living Radical Polymerization. Prog. Polym. Sci. 2013;38:445-461.

    Not in our library10.1016/j.progpolymsci.2012.09.004

  132. 132.

    Heřmánková E., Žák A., Poláková L., Hobzová R., Hromádka R., Širc J. Polymeric Bile Acid Sequestrants: Review of Design, in Vitro Binding Activities, and Hypocholesterolemic Effects. Eur. J. Med. Chem. 2018;144:300-317.

    Not in our library10.1016/j.ejmech.2017.12.015

  133. 133.

    Cameron N.S., Eisenberg A., Brown G.R. Amphiphilic Block Copolymers as Bile Acid Sorbents: 1. Synthesis of Polystyrene-b-Poly(N,N,N-Trimethylammoniumethylene Acrylamide Chloride). Biomacromolecules. 2002;3:116-123.

    Not in our library10.1021/bm015595k

  134. 134.

    Cameron N.S., Eisenberg A., Brown G.R. Amphiphilic Block Copolymers as Bile Acid Sorbents: 2. Polystyrene-b-Poly(N,N,N-Trimethylammoniumethylene Acrylamide Chloride): Self-Assembly and Application to Serum Cholesterol Reduction. Biomacromolecules. 2002;3:124-132.

    Not in our library10.1021/bm015596c

  135. 135.

    Bayati S., Galantini L., Knudsen K.D., Schillén K. Effects of Bile Salt Sodium Glycodeoxycholate on the Self-Assembly of PEO-PPO-PEO Triblock Copolymer P123 in Aqueous Solution. Langmuir. 2015;31:13519-13527.

    Not in our library10.1021/acs.langmuir.5b03828

  136. 136.

    Bayati S., Anderberg Haglund C., Pavel N.V., Galantini L., Schillén K. Interaction between Bile Salt Sodium Glycodeoxycholate and PEO-PPO-PEO Triblock Copolymers in Aqueous Solution. RSC Adv. 2016;6:69313-69325.

    Not in our library10.1039/c6ra12514j

  137. 137.

    Patel V., Ray D., Bahadur A., Ma J., Aswal V.K., Bahadur P. Pluronic®-Bile Salt Mixed Micelles. Colloids Surf. B. 2018;166:119-126.

    Not in our library10.1016/j.colsurfb.2018.03.001

  138. 138.

    Singla P., Singh O., Chabba S., Aswal V.K., Mahajan R.K. Sodium Deoxycholate Mediated Enhanced Solubilization and Stability of Hydrophobic Drug Clozapine in Pluronic Micelles. Spectrochim. Acta Part A Mol. Biomol. Spectrosc. 2018;191:143-154.

    Not in our library10.1016/j.saa.2017.10.015

  139. 139.

    Tasca E., Giudice A. Del, Galantini L., Schillén K., Giuliani A.M., Giustini M. A Fluorescence Study of the Loading and Time Stability of Doxorubicin in Sodium Cholate/PEO-PPO-PEO Triblock Copolymer Mixed Micelles. J. Colloid Interface Sci. 2019;540:593-601.

    Not in our library10.1016/j.jcis.2019.01.075

  140. 140.

    Tasca E., Andreozzi P., Del Giudice A., Galantini L., Schillén K., Giuliani A.M., de los Angeles Ramirez M., Moya S.E., Giustini M. Poloxamer/Sodium Cholate Co-Formulation for Micellar Encapsulation of Doxorubicin with High Efficiency for Intracellular Delivery: An in-Vitro Bioavailability Study. J. Colloid Interface Sci. 2020;579:551-561.

    Not in our library10.1016/j.jcis.2020.06.096

  141. 141.

    Schillén K., Galantini L., Du G., Del Giudice A., Alfredsson V., Carnerup A.M., Pavel N.V., Masci G., Nyström B. Block Copolymers as Bile Salt Sequestrants: Intriguing Structures Formed in a Mixture of an Oppositely Charged Amphiphilic Block Copolymer and Bile Salt. Phys. Chem. Chem. Phys. 2019;21:12518-12529.

    Not in our library10.1039/c9cp01744e

  142. 142.

    Du G., Del Giudice A., Alfredsson V., Carnerup A.M., Pavel N.V., Loh W., Masci G., Nyström B., Galantini L., Schillén K. Effect of Temperature on the Association Behavior in Aqueous Mixtures of an Oppositely Charged Amphiphilic Block Copolymer and Bile Salt. Polymer. 2020;206:122871.

    Not in our library10.1016/j.polymer.2020.122871

  143. 143.

    di Gregorio M.C., Gubitosi M., Travaglini L., Pavel N.V., Jover A., Meijide F., Vázquez Tato J., Sennato S., Schillén K., Tranchini F., et al. Supramolecular Assembly of a Thermoresponsive Steroidal Surfactant with an Oppositely Charged Thermoresponsive Block Copolymer. Phys. Chem. Chem. Phys. 2017;19:1504-1515.

    Not in our library10.1039/c6cp05665b

  144. 144.

    Pigliacelli C., Belton P., Wilde P., Qi S. Probing the Molecular Interactions between Pharmaceutical Polymeric Carriers and Bile Salts in Simulated Gastrointestinal Fluids Using NMR Spectroscopy. J. Colloid Interface Sci. 2019;551:147-154.

    Not in our library10.1016/j.jcis.2019.05.002

  145. 145.

    Carey M.C., Small D.M. Micellar Properties of Dihydroxy and Trihydroxy Bile Salts: Effects of Counterion and Temperature. J. Colloid Interface Sci. 1969;31:382-396.

    Not in our library10.1016/0021-9797(69)90181-7

  146. 146.

    Li Y., Holzwarth J.F., Bohne C. Aggregation Dynamics of Sodium Taurodeoxycholate and Sodium Deoxycholate. Langmuir. 2000;16:2038-2041.

    Not in our library10.1021/la9903705

  147. 147.

    Kawamura H., Murata Y., Yamaguchi T., Igimi H., Tanaka M., Sugihara G., Kratohvil J.P. Spin-Label Studies of Bile Salt Micelles. J. Phys. Chem. 1989;93:3321-3326.

    Not in our library10.1021/j100345a087

  148. 148.

    Campanelli A.R., de Sanctis S.C., Galantini L., Giglio E., Scaramuzza L. A Possible Helical Model for Sodium Glycocholate Micellar Aggregates. J. Incl. Phenom. Mol. Recognit. Chem. 1991;10:367-377.

    Not in our library10.1007/bf01133321

  149. 149.

    D’Archivio A.A., Galantini L., Gavuzzo E., Giglio E., Scaramuzza L. Possible Models for the Micellar Aggregates of Glycocholate and Taurocholate Salts from Crystal Structures, QELS, and CD Measurements. Langmuir. 1996;12:4660-4667.

    Not in our library10.1021/la9600558

  150. 150.

    Galantini L., Giglio E., Leonelli A., Pavel N.V. An Integrated Study of Small-Angle x-Ray Scattering and Dynamic Light Scattering on Cylindrical Micelles of Sodium Glycodeoxycholate. J. Phys. Chem. B. 2004;108:3078-3085.

    Not in our library10.1021/jp036746b

  151. 151.

    Galantini L., Giampaolo S.M., Mannina L., Pavel N.V., Viel S. Study of Intermicellar Interactions and Micellar Sizes in Ionic Micelle Solutions by Comparing Collective Diffusion and Self-Diffusion Coefficients. J. Phys. Chem. B. 2004;108:4799-4805.

    Not in our library10.1021/jp037328+

  152. 152.

    D’Archivio A.A., Galantini L., Tettamanti E. Study on Intermicellar Interactions and Micellar Size in Aqueous Solutions of Sodium Taurocholate by Measurements of Collective Diffusion and Self-Diffusion Coefficients. J. Phys. Chem. B. 2000;104:9255-9259.

    Not in our library10.1021/jp000070s

  153. 153.

    Zhang J., Wang H., Li X., Song S., Song A., Hao J. Two Gelation Mechanisms of Deoxycholate with Inorganic Additives: Hydrogen Bonding and Electrostatic Interactions. J. Phys. Chem. B. 2016;120:6812-6818.

    Not in our library10.1021/acs.jpcb.6b04140

  154. 154.

    Li G., Hu Y., Sui J., Song A., Hao J. Hydrogelation and Crystallization of Sodium Deoxycholate Controlled by Organic Acids. Langmuir. 2016;32:1502-1509.

    Not in our library10.1021/acs.langmuir.6b00019

  155. 155.

    McNeel K.E., Das S., Siraj N., Negulescu I.I., Warner I.M. Sodium Deoxycholate Hydrogels: Effects of Modifications on Gelation, Drug Release, and Nanotemplating. J. Phys. Chem. B. 2015;119:8651-8659.

    Not in our library10.1021/acs.jpcb.5b00411

  156. 156.

    Song S., Feng L., Song A., Hao J. Room-Temperature Super Hydrogel as Dye Adsorption Agent. J. Phys. Chem. B. 2012;116:12850-12856.

    Not in our library10.1021/jp3066025

  157. 157.

    Sun X., Xin X., Tang N., Guo L., Wang L., Xu G. Manipulation of the Gel Behavior of Biological Surfactant Sodium Deoxycholate by Amino Acids. J. Phys. Chem. B. 2014;118:824-832.

    Not in our library10.1021/jp409626s

  158. 158.

    di Gregorio M.C., Shimon L.J.W., Brumfeld V., Houben L., Lahav M., van der Boom M.E. Emergence of Chirality and Structural Complexity in Single Crystals at the Molecular and Morphological Levels. Nat. Commun. 2020;11:380.

    Not in our library10.1038/s41467-019-13925-5

  159. 159.

    Salzillo T., Giunchi A., Masino M., Bedoya-Martĺnez N., Della Valle R.G., Brillante A., Girlando A., Venuti E. An Alternative Strategy to Polymorph Recognition at Work: The Emblematic Case of Coronene. Cryst. Growth Des. 2018;18:4869-4873.

    Not in our library10.1021/acs.cgd.8b00934

  160. 160.

    Qiao Y., Lin Y., Wang Y., Yang Z., Liu J., Zhou J., Yan Y., Huang J. Metal-Driven Hierarchical Nanohelices. Nano Lett. 2009;9:4500-4504.

    Not in our library10.1021/nl9028335

  161. 161.

    Qiao Y., Wang Y., Yang Z., Lin Y., Huang J. Self-Templating of Metal-Driven Supramolecular Self-Assembly: A General Approach toward 1D Inorganic Nanotubes. Chem. Mater. 2011;23:1182-1187.

    Not in our library10.1021/cm102649y

  162. 162.

    Qiao Y., Lin Y., Zhang S., Huang J. Lanthanide-Containing Photoluminescent Materials: From Hybrid Hydrogel to Inorganic Nanotubes. Chem. A Eur. J. 2011;17:5180-5187.

    Not in our library10.1002/chem.201003255

  163. 163.

    Laishram R., Bhowmik S., Maitra U. White Light Emitting Soft Materials from Off-the-Shelf Ingredients. J. Mater. Chem. C. 2015;3:5885-5889.

    Not in our library10.1039/c5tc01072a

  164. 164.

    Laishram R., Maitra U. Bile Salt-Derived Eu3+ Organogel and Hydrogel: Water-Enhanced Luminescence of Eu3+ in a Gel Matrix. ChemistrySelect. 2018;3:519-523.

    Not in our library10.1002/slct.201701013

  165. 165.

    Wang H., Song S., Hao J., Song A. Hydrogels Triggered by Metal Ions as Precursors of Network CuS for DNA Detection. Chem. A Eur. J. 2015;21:12194-12201.

    Not in our library10.1002/chem.201500919

  166. 166.

    Shen J., Wang Y., Xin X., Xu G., Li W., Wang L., Jia C. Studies on the Gel Behavior and Luminescence Properties of Biological Surfactant Sodium Deoxycholate/Rare-Earth Salts Mixed Systems. J. Colloid Interface Sci. 2014;431:82-89.

    Not in our library10.1016/j.jcis.2014.06.013

  167. 167.

    Cheng C.Y., Oh H., Wang T.Y., Raghavan S.R., Tung S.H. Mixtures of Lecithin and Bile Salt Can Form Highly Viscous Wormlike Micellar Solutions in Water. Langmuir. 2014;30:10221-10230.

    Not in our library10.1021/la502380q

  168. 168.

    Markina A.A., Ivanov V.A., Komarov P.V., Khokhlov A.R., Tung S.H. Self-Assembly of Lecithin and Bile Salt in the Presence of Inorganic Salt in Water: Mesoscale Computer Simulation. J. Phys. Chem. B. 2017;121:7878-7888.

    Not in our library10.1021/acs.jpcb.7b04566

  169. 169.

    Cautela J., Giustini M., Pavel N.V., Palazzo G., Galantini L. Wormlike Reverse Micelles in Lecithin/Bile Salt/Water Mixtures in Oil. Colloids Surf. A Phys. Eng. Asp. 2017;532:411-419.

    Not in our library10.1016/j.colsurfa.2017.04.052

  170. 170.

    Njauw C.W., Cheng C.Y., Ivanov V.A., Khokhlov A.R., Tung S.H. Molecular Interactions between Lecithin and Bile Salts/Acids in Oils and Their Effects on Reverse Micellization. Langmuir. 2013;29:3879-3888.

    Not in our library10.1021/la304601p

  171. 171.

    Jean B., Oss-Ronen L., Terech P., Talmon Y. Monodisperse Bile-Salt Nanotubes in Water: Kinetics of Formation. Adv. Mater. 2005;17:728-731.

    Not in our library10.1002/adma.200401125

  172. 172.

    Terech P., Velu S.K.P., Pernot P., Wiegart L. Salt Effects in the Formation of Self-Assembled Lithocholate Helical Ribbons and Tubes. J. Phys. Chem. B. 2012;116:11344-11355.

    Not in our library10.1021/jp305365m

  173. 173.

    Zhang X., Zou J., Tamhane K., Kobzeff F.F., Fang J. Self-Assembly of PH-Switchable Spiral Tubes: Supramolecular Chemical Springs. Small. 2010;6:217-220.

    Not in our library10.1002/smll.200901067

  174. 174.

    Rhodes S., Liang W., Wang X., Reddy N.R., Fang J. Transition from H-Aggregate Nanotubes to J-Aggregate Nanoribbons. J. Phys. Chem. C. 2020;124:11722-11729.

    Not in our library10.1021/acs.jpcc.0c02908

  175. 175.

    Zhang X., Bera T., Liang W., Fang J. Longitudinal Zipping/Unzipping of Self-Assembled Organic Tubes. J. Phys. Chem. B. 2011;115:14445-14449.

    Not in our library10.1021/jp2064276

  176. 176.

    D’Alagni M., Delfini M., Galantini L., Giglio E. A Study of the Interaction of Bilirubin Wtth Sodium Deoxycholate in Aqueous Solutions. J. Phys. Chem. 1992;96:10520-10528.

    Not in our library10.1021/j100204a073

  177. 177.

    D’Alagni M., D’Archivio A.A., Giglio E., Scaramuzza L. Structure of Sodium and Rubidium Taurodeoxycholate Micellar Aggregates and Their Interaction Complexes with Bilirubin-IXα. J. Phys. Chem. 1994;98:343-353.

    Not in our library10.1021/j100052a056

  178. 178.

    Meier A.R., Yehl J.B., Eckenroad K.W., Manley G.A., Strein T.G., Rovnyak D. Stepwise Aggregation of Cholate and Deoxycholate Dictates the Formation and Loss of Surface-Available Chirally Selective Binding Sites. Langmuir. 2018;34:6489-6501.

    Not in our library10.1021/acs.langmuir.8b00467

  179. 179.

    Singh K., Chauhan S. Temperature Dependent Micellar Behaviour of Sodium Cholate and Sodium Deoxycholate in the Presence of Ceftriaxone Sodium: A Physicochemical Study. J. Mol. Liq. 2020;316:113833.

    Not in our library10.1016/j.molliq.2020.113833

  180. 180.

    Zhang Q., Ma X., Ward A., Hong W.X., Jaakola V.P., Stevens R.C., Finn M.G., Chang G. Designing Facial Amphiphiles for the Stabilization of Integral Membrane Proteins. Angew. Chem. Int. Ed. 2007;46:7023-7025.

    Not in our library10.1002/anie.200701556

  181. 181.

    Gubitosi M., Trillo J.V., Alfaro Vargas A., Pavel N.V., Gazzoli D., Sennato S., Jover A., Meijide F., Galantini L. Characterization of Carbon Nanotube Dispersions in Solutions of Bile Salts and Derivatives Containing Aromatic Substituents. J. Phys. Chem. B. 2014;118:1012-1021.

    Not in our library10.1021/jp407145t

  182. 182.

    di Gregorio M.C., Varenik M., Gubitosi M., Travaglini L., Pavel N.V., Jover A., Meijide F., Regev O., Galantini L. Multi Stimuli Response of a Single Surfactant Presenting a Rich Self-Assembly Behavior. RSC Adv. 2015;5:37800-37806.

    Not in our library10.1039/c5ra01394a

  183. 183.

    di Gregorio M.C., Pavel N.V., Jover A., Meijide F., Vázquez Tato J., Soto Tellini V.H., Vargas A.A., Regev O., Kasavi Y., Schillén K., et al. PH Sensitive Tubules of a Bile Acid Derivative: A Tubule Opening by Release of Wall Leaves. Phys. Chem. Chem. Phys. 2013;15:7560-7566.

    Not in our library10.1039/c3cp00121k

  184. 184.

    Galantini L., Leggio C., Jover A., Meijide F., Pavel N.V., Soto Tellini V.H., Vázquez Tato J., Di Leonardo R., Ruocco G. Kinetics of Formation of Supramolecular Tubules of a Sodium Cholate Derivative. Soft Matter. 2009;5:3018-3025.

    Not in our library10.1039/b905531b

  185. 185.

    Vázquez Tato J., Meijide F., Antelo A., Alvarez Alcalde M., Jover A., Galantini L., Pavel N.V. Supramolecular Structures Generated by a P-Tert-Butylphenylamide Derivative of Deoxycholic Acid. from Planar Sheets to Tubular Structures through Helical Ribbons. Langmuir. 2010;26:7768-7773.

    Not in our library10.1021/la904548k

  186. 186.

    Meijide F., Trillo J.V., de Frutos S., Galantini L., Pavel N.V., Soto V.H., Jover A., Vázquez Tato J. Formation of Tubules by P-Tert-Butylphenylamide Derivatives of Chenodeoxycholic and Ursodeoxycholic Acids in Aqueous Solution. Steroids. 2012;77:1205-1211.

    Not in our library10.1016/j.steroids.2012.07.017

  187. 187.

    Margulis-Goshen K., di Gregorio M.C., Pavel N.V., Abezgauz L., Danino D., Vázquez Tato J., Soto Tellini V.H., Magdassi S., Galantini L. Drug-Loaded Nanoparticles and Supramolecular Nanotubes Formed from a Volatile Microemulsion with Bile Salt Derivatives. Phys. Chem. Chem. Phys. 2013;15:6016-6024.

    Not in our library10.1039/c3cp50258a

  188. 188.

    Trillo J.V., Jover A., Galantini L., Tato J.V., Soto V.H., Meijide F., di Gregorio M.C., de Frutos S. Self-Aggregation Mechanism of a Naphthylamide Cationic Derivative of Cholic Acid. From Fibers to Tubules. RSC Adv. 2013;4:5598-5606.

    Not in our library10.1039/c3ra47160h

  189. 189.

    Travaglini L., D’Annibale A., Schillén K., Olsson U., Sennato S., Pavel N.V., Galantini L. Amino Acid–Bile Acid Based Molecules: Extremely Narrow Surfactant Nanotubes Formed by a Phenylalanine-Substituted Cholic Acid. Chem. Commun. 2012;48:12011-12013.

    Not in our library10.1039/c2cc36030f

  190. 190.

    Travaglini L., D’Annibale A., di Gregorio M.C., Schillén K., Olsson U., Sennato S., Pavel N.V., Galantini L. Between Peptides and Bile Acids: Self-Assembly of Phenylalanine Substituted Cholic Acids. J. Phys. Chem. B. 2013;117:9248-9257.

    Not in our library10.1021/jp405342v

  191. 191.

    Travaglini L., Gubitosi M., di Gregorio M.C., Pavel N.V., D’Annibale A., Giustini M., Soto Tellini V.H., Vázquez Tato J., Obiols-Rabasa M., Bayati S., et al. On the Self-Assembly of a Tryptophan Labeled Deoxycholic Acid. Phys. Chem. Chem. Phys. 2014;16:19492-19504.

    Not in our library10.1039/c4cp02371d

  192. 192.

    Travaglini L., Gubitosi M., di Gregorio M.C., D’Annibale A., Meijide F., Giustini M., Sennato S., Obiols-Rabasa M., Schillén K., Pavel N.V., et al. A Tryptophan-Substituted Cholic Acid: Expanding the Family of Labelled Biomolecules. Colloids Surf. A Phys. Eng. Asp. 2015;483:142-149.

    Not in our library10.1016/j.colsurfa.2015.03.033

  193. 193.

    Gubitosi M., Travaglini L., D’Annibale A., Pavel N.V., Vázquez Tato J., Obiols-Rabasa M., Sennato S., Olsson U., Schillén K., Galantini L. Sugar-Bile Acid-Based Bolaamphiphiles: From Scrolls to Monodisperse Single-Walled Tubules. Langmuir. 2014;30:6358-6366.

    Not in our library10.1021/la500908r

  194. 194.

    Gubitosi M., D’Annibale A., Schillén K., Olsson U., Pavel N.V., Galantini L. On the Stability of Lithocholate Derivative Supramolecular Tubules. RSC Adv. 2017;7:512-517.

    Not in our library10.1039/c6ra26092f

  195. 195.

    Soto Tellini V.H., Jover A., Meijide F., Vázquez Tato J., Galantini L., Pavel N.V. Supramolecular Structures Generated by a P-Tert-Butylphenylamide Derivative of Cholic Acid: From Vesicles to Molecular Tubes. Adv. Mater. 2007;19:1752-1756.

    Not in our library10.1002/adma.200602581

  196. 196.

    Manghisi N., Leggio C., Jover A., Meijide F., Pavel N.V., Tellini V.H.S., Tato J.V., Agostino R.G., Galantini L. Catanionic Tubules with Tunable Charge. Angew. Chem. Int. Ed. 2010;49:6604-6607.

    Not in our library10.1002/anie.201000951

  197. 197.

    di Gregorio M.C., Severoni E., Travaglini L., Gubitosi M., Sennato S., Mura F., Redondo-Gómez C., Jover A., Pavel N.V., Galantini L. Bile Acid Derivative-Based Catanionic Mixtures: Versatile Tools for Superficial Charge Modulation of Supramolecular Lamellae and Nanotubes. Phys. Chem. Chem. Phys. 2018;20:18957-18968.

    Not in our library10.1039/c8cp02745e

  198. 198.

    Gubitosi M., Travaglini L., di Gregorio M.C., Pavel N.V., Vazquez-Tato J., Sennato S., Olsson U., Schillén K., Galantini L. Tailoring Supramolecular Nanotubes by Bile Salt Based Surfactant Mixtures. Angew. Chem. Int. Ed. 2015;54:7018-7021.

    Not in our library10.1002/anie.201500445

  199. 199.

    Cautela J., Lattanzi V., Månsson L., Galantini L., Crassous J.J. Sphere–Tubule Superstructures through Supramolecular and Supracolloidal Assembly Pathways. Small. 2018;14:1803215.

    Not in our library10.1002/smll.201803215

  200. 200.

    Gubitosi M., Meijide F., D’Annibale A., Vázquez Tato J., Jover A., Galantini L., Travaglini L., di Gregorio M.C., Pavel N.V. Crystal Structure of a Lithium Salt of a Glucosyl Derivative of Lithocholic Acid. Steroids. 2016;113:87-94.

    Not in our library10.1016/j.steroids.2016.07.001

  201. 201.

    Cautela J., Severoni E., Redondo-Gómez C., di Gregorio M.C., Del Giudice A., Sennato S., Angelini R., D’Abramo M., Schillén K., Galantini L. Substituent Position and Orientation on the Self-Assembly of Steroid Surfactant Isomers. Colloids Surf. B. 2020;185:110556.

    Not in our library10.1016/j.colsurfb.2019.110556

  202. 202.

    di Gregorio M.C., Ranjan P., Houben L., Shimon L.J.W., Rechav K., Lahav M., Van Der Boom M.E. Metal-Coordination-Induced Fusion Creates Hollow Crystalline Molecular Superstructures. J. Am. Chem. Soc. 2018;140:9132-9139.

    Not in our library10.1021/jacs.8b03055

  203. 203.

    Travaglini L., di Gregorio M.C., Severoni E., Annibale A.D., Sennato S., Tardani F., Giustini M., Gubitosi M., Del A., Galantini L. Deoxycholic Acid and L -Phenylalanine Enrich Their Hydrogel Properties When Combined in a Zwitterionic Derivative. J. Colloid Interface Sci. 2019;554:453-462.

    Not in our library10.1016/j.jcis.2019.07.019

  204. 204.

    Pore V.S., Agalave S.G., Pharande S.G., Patil P.A., Kotmale A.S. Bile Acid Hydrazides: Gelation, Structural, Physical and Spectroscopic Properties. New J. Chem. 2015;39:453-460.

    Not in our library10.1039/c4nj01352b

  205. 205.

    Travaglini L., Giordano C., D’Annibale A., Gubitosi M., di Gregorio M.C., Schillén K., Stefanucci A., Mollica A., Pavel N.V., Galantini L. Twisted Nanoribbons from a RGD-Bearing Cholic Acid Derivative. Colloids Surf. B. 2017;159:183-190.

    Not in our library10.1016/j.colsurfb.2017.07.084

  206. 206.

    Noponen V., Valkonen A., Lahtinen M., Salo H., Sievänen E. Self-Assembly Properties of Bile Acid Derivatives of L-Cysteine, L-Valine and L-Serine Alkyl Esters. Supramol. Chem. 2013;25:133-145.

    Not in our library10.1080/10610278.2012.735365

  207. 207.

    Sajisha V.S., Maitra U. Remarkable Isomer-Selective Gelation of Aromatic Solvents by a Polymorph of a Urea-Linked Bile Acid– Amino Acid Conjugate. RSC Adv. 2014;4:43167-43171.

    Not in our library10.1039/c4ra08957j

  208. 208.

    Maity M., Maitra U. Supramolecular Gels from Conjugates of Bile Acids and Amino Acids and Their Applications. Eur. J. Org. Chem. 2017;2017:1713-1720.

    Not in our library10.1002/ejoc.201601616

  209. 209.

    di Gregorio M.C., Pavel N.V., Miragaya J., Jover A., Meijide F., Vázquez Tato J., Soto Tellini V.H., Galantini L. Catanionic Gels Based on Cholic Acid Derivatives. Langmuir. 2013;29:12342-12351.

    Not in our library10.1021/la402602d

  210. 210.

    Chiang J.Y.L. Bile Acid Metabolism and Signaling. Compr. Physiol. 2013;3:1191-1212.

    Not in our library10.1002/cphy.c120023

  211. 211.

    De Aguiar Vallim T.Q., Tarling E.J., Edwards P.A. Pleiotropic Roles of Bile Acids in Metabolism. Cell Metab. 2013;17:657-669.

    Not in our library10.1016/j.cmet.2013.03.013

  212. 212.

    Wahlström A., Sayin S.I., Marschall H.U., Bäckhed F. Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism. Cell Metab. 2016;24:41-50.

    Not in our library10.1016/j.cmet.2016.05.005

  213. 213.

    Wu Y., Zhou A., Tang L., Lei Y., Tang B., Zhang L. Bile Acids: Key Regulators and Novel Treatment Targets for Type 2 Diabetes. J. Diabetes Res. 2020;2020:6138438.

    Not in our library10.1155/2020/6138438

  214. 214.
    Bile Acid Signaling in Neurodegenerative and Neurological Disorders · 2020
    No notice

Cited by papers we hold 1

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.